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by
Sheng Xiong
Advisor: Professor Cathy Savage-Dunn
TGFβ signaling is a conserved signaling pathway among eukaryotes, which controls
various normal cellular responses from cell proliferation to cell death. The mutations in its
components are found in developmental disorders and cancer. Therefore, this signaling pathway
is extensively investigated so that new therapeutic targets could be discovered and novel drugs
could be developed. Previous studies suggested the involvement of phosphatases in regulation of
TGFβ signaling, but these studies were performed in cell culture rather than intact organisms. C.
elegans is a tractable organism in which to study signaling in vivo. In C. elegans, growth is
controled by a conserved TGFβ pathway, the Sma/Mab pathway.
We used a C. elegans RNA interference library of phosphatases to identify genes that
cause a body size phenotype. Library-wide screening was carried out in an RNAi-hypersensitive
mutant background, rrf-3. To further narrow the candidate pool, we analyzed the body size
phenotypes of these candidates using different genetic backgrounds. These analyses allow us to
narrow the candidate pool down to 80-candidates.
A Sma/Mab pathway reporter, RAD-SMAD reporter (a kind gift from Dr. Jun Liu,
Cornell University), was used to assess whether the candidates regulate body size phenotype in a
Sma/Mab pathway-dependent manner or not. The reporter assay revealed 22 likely candidates
regulate Sma/Mab signaling directly or indirectly. Among them, 11 candidates were verified as
protein phosphatases by sequencing. These include homologues of mammalian PPM1A/B/G and
PP1.
iv

Our study revealed that ppm-1 (metal-ion dependent protein phosphatase-1), a human
PPM1A/B/G homolog, might act as a potential SMA-3-specific linker phosphatase to regulate
the Sma/Mab pathway. This is the first time to show that a homolog of human PPM1A/B/G
might act as a potential linker phosphatase of R-Smads to promote TGFβ signaling. Our studies
also showed that a homolog of the inhibitory regulatory subunit of human PP1 might synergize
with the catalytic subunit in the regulation of TGFβ signaling for the first time. We also
discovered the regulatory role of several protein tyrosine phosphatases in this signaling cascade.
In summary, this study sheds a light on elucidating the regulatory mechanism of TGFβ signaling
pathway, therefore providing insight in various TGFβ signaling-involved human developmental
disorders and cancer, and contributing to the development of potential diagnostic markers and
therapeutic targets in human diseases.
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Chapter I: Introduction
I.1

C. elegans: a classic genetic model organism
In 1965, Sydney Brenner first introduced Caenorhabditis elegans as a model system to

study animal genetics, development and behavior. And it rapidly turned to be a popular tool for
scientists to study almost all fundamental biological processes, including embryonic and postembryonic development, neurobiology, apoptosis, signal transduction, and evolution as well.
Meanwhile, it was also used to build disease models to uncover underlying mechanisms, seeking
for potential clinical therapy and drug discovery.
Compared to other well developed model organisms, such as Drosophila, zebrafish and
mice, C. elegans offers a lot of advantages for genetic studies, especially for understanding
developmental processes. It has a rapid life cycle, transparent body and is easy for laboratory
cultivation. In addition, its relatively small and fully sequenced genome, well defined cell lineage
and easy transformation add credits to its popularity for various study purposes.

I.1.1. Rapid life cycle.
C. elegans has a rapid life cycle: around 3 days for each generation at 20°C and a
relatively large number of progeny: each single hermaphrodite can give rise to 300-350 progeny
(Wormbook.org). Normal C. elegans has six developmental stages: eggs, L1, L2, L3, L4, and
adult (Figure 1.1). At 22°C, embryogenesis requires approximately 14 hours and the postembryonic development from first larval stage (L1) stage to adult needs 36 hours. In each
developmental stage, a stage-specific cuticle is secreted by the hypodermis. As a result, molting
the old cuticle and forming a new one is the indication of stage change (Page and Johnstone,
2007).
1

Figure 1.1 Life cycle of C. elegans at 22°C (WormAtlas.org)
Under unfavorable living conditions, for example, lack of food, high temperature and
overcrowded growth, worms in L2 stage would go into a non-developmental stage, the dauer
stage, instead of the L3 stage. Worms that enter the dauer stage change their energy metabolism,
accumulating fat and altering their behavior strikingly. In addition, a specific cuticle replaces the
one for L2 (Hu, 2007). Dauer larvae can survive for months, approximately ten times their
normal life span. When the environment changes back to favorable conditions, they resume
development into the L4 stage, bypassing L3 stage.
C. elegans has a transparent body throughout development. This is a great advantage for
us to examine cells in vivo and mutant phenotypes. In addition, the cell number and their position
2

are consistent among individuals. Adult worms have less than 1,000 cells (excluding germ cells),
including 302 neurons in hermaphrodites or 381 neurons in males. The entire cell lineage, from
egg to adult, is essentially the same in each animal and is known precisely (Sulston et al. 1977,
1983). This benefits studies on cell fate determination in embryonic and post-embryonic
development.
The hermaphrodites and rare males are another key characteristic for C. elegans. As a
result, self fertilization and cross fertilization coexist in C. elegans. The hermaphrodites are
protandrous, first producing sperm in late L4 stage, storing them in its spermathecae, and then
turning to produce oocytes. Rare males can mate with hermaphrodites, stimulating the
production of oocytes by hermaphrodites. Thereby, homozygotic and heterozygotic animals can
be easily obtained from mutagenesis or cross. Meanwhile, easy transformation of C. elegans by
microinjection makes them suitable for genetic analysis. And one can knockdown specific genes
using dsRNA through both microinjection and feeding, which facilitates the elucidation of
interested target gene function.
Furthermore, C. elegans has a small genome, about 97 million base pairs. Approximately,
19,099 genes (The C. elegans Sequencing Consortium 1998) are predicted and only 6% of them
have been studied genetically or biochemically. There are still a large number of genes whose
functions are unknown. This provides a challenging field for researchers to explore.

I.1.2. Anatomy of C. elegans
Basically, like other nematodes, the body of C. elegans is made up of two concentric
tubes separated by a fluid-filled space, the pseudocoelom. The animal’s shape is maintained by
internal hydrostatic pressure. The outer tube contains the nervous system, gonad, coelomcytes,
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and excretory/secretory system and is covered by the collagenous, extracellular cuticle, which is
secreted by the underlying hypodermis. The inner tube is composed of the muscular pharynx
with its nearly autonomous nervous system, intestine, rectum and anus (Figure 1.2).

Figure 1.2 Photomicrographs showing major anatomical features of
the C. elegans adult hermaphrodite (top) and male (bottom). Shown
are lateral views under bright field illumination (Sulston & Horvitz, 1977).

The copulatory bursa in the male tail includes two spicules, a fan, and 18 sensory rays.
The fan is an extended acellular structure of cuticle matrix. The sensory rays are distinguished
into two identical groups that are one-axis symmetrical along the ventral midline. Each group
contains nine different rays numbered 1 through 9 from anterior to posterior (Nguyen et al.,
1999). Each ray contains two neurons, RNA and RNB that express different neurotransmitters,
and one support cell surrounded by a hypodermal sheath. For example, dopamine is expressed
only in the ray5A, ray 7A, and ray 9A neurons (Lints & Emmons, 1999). Rays 1, 5, and 7
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localize at the dorsal side of the fan; rays 3, 6, and 9 at the edge; rays 2, 4, and 8 at the ventral
side. The Sma/Mab mutants have defects in the male tail, which will be discussed in detail later.

I.2

Transforming growth factor-β (TGF-β) signaling pathway
The transforming growth factor β (TGF-β) superfamily comprises structurally related

polypeptide growth factors, including TGF-βs, bone morphogenetic proteins (BMPs), growth
and differentiation factors (GDFs), Activins and Nodal (Feng and Derynck, 2005). Each member
is capable of regulating a large number of biological processes including cell proliferation,
lineage determination, differentiation, motility, adhesion, and death. These TGF-β superfamily
ligands, as well as their downstream pathway components, are well conserved during evolution
and the signal transduction pathway is relatively simple and linear. Active TGF-β ligand dimer
brings together two pairs of transmembrane receptor serine/threonine kinases known as type II
and type I receptors. Upon binding TGF-βs, type II receptor phosphorylates and activates type I
receptor. The intracellular signal transducers (R-Smads) are then phosphorylated by type I
receptor, and in turn, form complexes with Co-Smad. Those Smad complexes accumulate in the
nucleus, with the help of other transcriptional cofactors, modulating transcription of target genes
(Fig. 1.3). Basically, TGF-β and activins signal their transcription responses through Smad2 and
Smad3, whereas BMPs signal through Smad1, Smad5 and Smad8 (Feng and Derynck. 2005).

5

Figure 1.3 Transforming growth factor-β (TGFβ) signaling pathway (Feng
and Derynck, 2005)
6

I.2.1. TGF-β ligands
Based on structural and functional relatedness, the large TGF-β superfamily is divided
into two subfamilies: the TGF-β isoforms, Nodal, and Activins family, and the BMPs and GDFs
family. The TGF-β superfamily comprises more than 30 genes in mammals, 7 genes in
Drosophila and 5 genes in C. elegans. The ligands are expressed and secreted into the
extracellular matrix (ECM) as dimeric pre-proproteins. Dimerization and stabilization require the
pro-domain (Gray and Mason, 1990). The mature ligands are cleaved from the prodomain by
furin-like convertase (Dubois et al., 1995). Most frequently, ligand dimerizes with itself.
However, heterodimerization is also observed, for example in mammals between Nodal and
BMP4 or BMP7 (Yeo and Whitman, 2001), and in Drosophila, between Dpp and Scw (Shimmi
et al., 2005). A major regulatory step in TGF-β signaling is the regulation of ligand accessibility
by extracellular ligand binding proteins.

I.2.2. TGF-β receptors
Compared to the large number of TGF-β ligands, there are only five type II receptors
(TβRII) and seven type I receptors (TβRI) identified in humans. They are transmembrane
serine/threonine kinases, which contain a short extracellular region (Wells et al., 1997), a
transmembrane domain and a cytoplasmic serine/threonine kinase domain. TGF-β binding
stabilizes the interaction of the TβRII dimer with two TβRI molecules, forming heterotetrameric,
active receptor complexes (Feng and Derynck, 2005). The assembly of the active receptor
complexes is different for different ligands. In the case of TGF-β receptors, ligand-bound high
affinity type II receptor will recruit type I receptor and this process is facilitated by direct
interaction between type II and type I receptor. However, the BMP receptors do not interact
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directly. They are linked via the ligands (Groppe et al., 2008).
Considering the relatively small number of TGF-β receptors, it is becoming apparent that
different ligand-receptor interactions and type II and type I receptor pairings exist (Feng and
Derynck, 2005), which can possibly account in part for the huge diversity of the TGF-β signaling
outputs. Indeed, in endothelial cells, TGF-β can activate both ALK1 and ALK5, and a complex
has been proposed comprising these two distinct type I receptors (Goumans et al., 2003).
Recently, mixed receptor complexes containing TβRII, ALK5, and either ALK2 or ALK3 have
been reported to mediate a novel branch of TGF-β signaling in epithelial cells (Daly et al., 2008).
In Drosophila, a receptor complex comprising the type I receptor Thickveins (Tkv) and
Saxophone (Sax) and the type II receptor Punt have also been observed (O’Connor et al., 2006).
Upon ligand binding, the cytoplasmic kinase domain of type II receptor will
phosphorylate the GS domain on type I receptor, which in turn activates type I receptor kinase
activity. Then the activated type I receptor will phosphorylate Smad proteins and transduce the
signal downstream. The nine-amino acid L45 loop in the kinase domain of type I receptor is the
critical motif that contributes to the receptor-Smad protein interaction. Huse et al. showed from
the crystal structure of type I receptor that the L45 loop is accessible for protein interactions
(Huse et al., 2001). Meanwhile, receptors with different signaling specificity have different L45
sequences (Chen et al., 1998; Feng & Derynck, 1997).

I.2.3. Smad proteins
Smad family proteins are the well established intracellular effectors in TGF-β signaling.
The founding member of the Smad family is the product of the Drosophila gene Mad (mothers
against dpp) (Sekelsky et al., 1995), followed by three Mad homologues identified in C. elegans,
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called sma-2, sma-3, and sma-4 (Savage et al., 1996, Derynck et al., 1998). Later on, many
homologues were discovered in vertebrates and named Smad (merge of MAD and SMA). Smads
exist in three subgroups: (1) receptor-regulated Smads (R-Smads), e.g. Smad1, 2, 3, 5, and 8 in
vertebrates, Mad in Drosophila, SMA-2 and -3, and DAF-8 and -14 in C. elegans; (2), common
Smads (Co-Smads) e.g. Smad4 in vertebrates, Medea in Drosophila, SMA-4, and DAF-3 in C.
elegans; (3) inhibitory Smads (I-Smads), e.g. Smad6 and 7 in vertebrates and Dad in Drosophila.
R-Smads and Co-Smads contains highly conserved MH1 (N-terminal) and MH2 (Cterminal) domains linked by a more divergent linker region. The MH1 domain has approximately
130 amino acids and contributes to the DNA-binding activity. R-Smads can directly interact with
type I receptor through the MH2 domain and have a C-terminal SXS motif in which two serines
are direct targets for phosphorylation by type I receptor. Phosphorylation of SXS motif in RSmads leads to a conformational change, resulting in dissociation of R-Smad from type I
receptor and formation of a trimeric Smad complex consisting of two R-Smads and a Co-Smad.
This trimeric Smad complex then accumulates in the nucleus and regulates gene expression,
positively or negatively, usually in association with other transcriptional cofactors (Moustakas &
Heldin, 2009; Feng & Derynck, 2005; Derynck & Zhang, 2003; Shi & Massague, 2003).
Since R-Smads localize in the cytoplasm, efficient R-Smad recruitment and activation in
response to TGF-β and activin requires other accessory proteins. SARA (Smad Anchor for
Receptor Activation), an FYVE domain-containing, plasma membrane localized and EEA-1
positive endosome enriched protein, can interact with type I receptor and Smad2/3 and recruits
Smad2 to the receptor for phosphorylation (Wu et al., 2000). Thus, complex formation of the
receptors with Smads and SARA at EEA-1 positive endosome can promote TGF-β signaling (Di
Guglielmo et al., 2003). Hgs, another FYVE domain protein involved in endosomal trafficking,
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may play a role similar to that of SARA, since it also interacts with Smad2 and Smad3 and
enhances ligand-induced Smad phosphorylation and gene expression (Miura et al., 2000).
Inhibitory Smads (I-Smads), like Smad6 and Smad7 which are induced by TGF-β family
ligands, inhibit TGF-β signaling through various mechanisms (Hayashi et al., 1997; Imamura et
al., 1997; Nakao et al., 1997). For example, Smad7 is shown to form a stable complex with type I
receptors, therefore leading to inhibition of R-Smad phosphorylation and the hetero-complex
formation between R-Smads and Co-Smad (Hayashi et al. 1997). Smad7 can also recruit the
HECT type of E3 ubiquitin ligases, Smurf1 and Smurf2 to the activated type I receptor
ALK5/TbRI, leading to the degradation of the receptor through the proteasomal pathway
(Ebisawa et al., 2001; Kavsak et al., 2000).

I.3

Reversible phosphorylation: an essential regulatory mechanism among species
Reversible phosphorylation of proteins is a major mechanism regulating multiple normal

biological processes such as metabolism, gene transcription, cell cycle and abnormal biological
processes such as carcinogenesis and angiogenesis. It is extremely common in signal
transduction, and it is considered the main posttranslational modification mechanism leading to a
change in enzyme activity. Phosphorylation state of a cetain protein results from a balance of
protein kinase and protein phosphatase activity. Alteration of the phosphorylation state of
proteins is often a cause of various diseases, such as cancer, diabetes, rheumatoid arthritis, or
hypertension. The importance of this regulatory mechanism is evident considering that the
number of genes encoding phosphatases and kinases represents 2 to 4% all genes in a typical
eukaryotic genome (Manning et al., 2002).
In eukaryotic cells, phosphorylation mainly occurs on three hydroxyl-containing amino
10

acids, serine, threonine, and tyrosine, of which serine is the predominant target. Proteomic study
of 6,600 phosphorylation sites on 2,244 human proteins revealed that phosphoserine (pSer),
phosphothreonine (pThr), and phosphotyrosine (pTyr) account for 86.4%, 11.8%, and 1.8%,
respectively, of the phosphorylated amino acids (Olson et al., 2006). The fully sequenced human
genome is thought to contain 518 putative protein kinases (Johnson and Hunter, 2005; Lander et
al., 2001; Venter et al., 2001) that can be classified into two families: 90 tyrosine (Tyr) kinases
(PTKs) and 428 serine/threonine (Ser/Thr) kinases (PSKs). The exquite specificity of signaling
and reversible phosphorylation seems to suggest there would be similar number of corresponding
protein phosphatases in the human genome. Surprisingly, there are 107 putative protein Tyr
phosphatases (PTPs) (Alson et al., 2004) and far fewer protein Ser/Thr phosphatases (PSPs)
(~30). Whereas the PTKs and PTPs are roughly matching each other, the number of catalytic
PSPs is an order of magnitude lower than that of PSKs. This dichotomy can be explained by the
combinatorial formation of PSP holoenzymes from a shared catalytic subunit and a large number
of regulatory subunits (Shi, 2009).
As mentioned before, most phosphorylation events in eukaryotes involve transfer of
phosphate to serine (Ser) and threonine (Thr) residues. Removal of this phosphate is catalyzed by
Ser/Thr protein phosphatases. Members of the large protein phosphatase family were initially
classified, using enzymological criteria, as type 1 (PP1) and type 2 (PP2) phosphatases. PP2
enzymes were subsequently divided into three groups on the basis of the requirements for metal
ions: 2A (not requiring metal ions), 2B (activated by calcium), and 2C (Mg2+/Mn2+-dependent)
(Shi, 2009). The molecular cloning of a number of cDNAs and genes from diverse organisms
allowed the establishment of three major subfamilies: PPP (phosphoprotein phosphatases),
including type 1, 2A, and 2B phosphatases; PPM (metal-dependent protein phosphatases),
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including type 2C enzymes (PP2C); and the catalytically asparate (Asp)-based subfamily,
represented by HAD and FCP/SCP (TFIIF-associating component of RNA polymerase II CTD
phosphatase/small CTD phosphatase)(Shi, 2009, Figure 1.4).
For several members of the PPP family, the catalytic subunit associates with a great
variety of regulatory subunits. Representative members include PP1, PP2A/PP2, PP2B/PP3
(commonly known as calneurin), PP4, PP5, PP6 and PP7 (Figure 1.4). The PPM family includes
protein phosphatases dependent on manganese/magnesium ions (Mn2+/Mg2+), such as PP2C and
pyruvate dehydrogenase phosphatase. In contrast to PPP, members of the PPM family do not
have regulatory subunits but contain instead additional domains and conserved sequence motifs
that may help determine substrate specificity. For both PPP and PPM, metal ions play a catalytic
and central role through the activation of a water molecule for the dephosphorylation reaction. In
contrast, FCP/SCP uses an asparate-based catalysis mechanism. The only known substrate of
FCP/SCP for a long time is the C-terminal domain (CTD) of RNA polymerase II, which contains
tandem repeats of a serine-rich heptapeptide. The conserved structural domain of FCP/SCP is the
FCP homology (FCPH) domain. FCPs, But not SCPs, contain a BRCT (BRCA1 C-terminal
domain like) domain that is C-terminal to the FCPH domain.
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Figure 1.4 The three families of protein serine/threonine phosphatases (Shi,
2009)

I.3.1

The PPP family of protein phosphatases
Representative members include PP1, PP2A/PP2, PP2B/PP3 (commonly known as

calcineurin), PP4, PP5, PP6 and PP7. As mentioned before, most members in the PPP family
function as a multiple-subunit holoenzymes regulating diverse biological processes.
Among them, PP1 is a major protein Ser/Thr phosphatase ubiquitously expressed in all
eukaryotic cells. Each functional PP1 enzyme consists of a catalytic subunit and a regulatory
subunit. The catalytic subunit is highly conserved among all eukaryotes with approximately 70%
or greater protein sequence identity in any pair-rise alignment. These identical sequences support
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a conserved fold and a similarily positioned active site for all PPP family members. The catalytic
subunit of PP1 adopts a compact α/β fold, with a β sandwich wedged between two α-helical
domains (Egloff et al., 1995; Goldberg et al., 1995). Coordination of the critical metal ions, Mn2+
and Fe2+, located in the active site, is provided by three histidines, two aspartic acids, and one
asparagine. These residues are highly conserved in all members of the PPP family, suggesting a
common mechanism of metal-catalyzed reaction in the protein family.
At least 100 putative PP1-binding regulatory subunits (R subunits) have been identified,
with many more expected to be found (Cohen, 2004; Moorhead et al., 2007). These R subunits
may target the PP1 catalytic subunit to specific subcellular compartment, modulate substrate
specificity, or serve as substrates themselves. Thus the interaction between the catalytic subunit
and specific R subunits are central to the function of PP1.
The phosphatase activity of PP1 is regulated by a number of endogenous inhibitory
proteins such as inhibitor-1 (I-1) (Nimmo and cohen, 1978), inhibitor-2 (I-2) (Foulkes and Cohen,
1980), CPI-17 (Eto et al., 1997), and DARPP-32 (Walaas and Greengard, 1991). Despite the
sequence conservation, PP2A/PP2 and PP2B/PP3 are not sensitive to inhibition by I-1 or I-2,
which forms the basis for classification of type 1 (PP1) versus type 2/3 phosphatases (Ingebritsen
and Cohen, 1983).
PP2A/PP2, one of the most abundant enzymes, accounts for up to 1% of the total cellular
protein in some tissues. Cellular PP2A exist in two general forms, a heterodimeric core enzyme
and a heterotrimeric holoenzyme. The PP2A core enzyme consists of a scaffold subunit (also
known as the A or PR65 subunit) and a catalytic subunit (C subunit). Both the A subunit and C
subunit have two isoforms, α and β, with the α isoform being about 10 times abundant than the β
isoform (Shi, 2009). The core enzyme interacts with a variable regulatory subunit to assemble
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the holoenzyme. The regulatory subunit comprises of four families: B (also known as B55 or
PR55), B’ (B56 or PR61), B’’ (PR48/PR72/PR130), and B’’’ (PR93/PR110). Each family
contains two to five isoforms that are encoded by different genes; some isoforms have multiple
splice variants. Diverse regulatory subunits are believed to confer exquisite substrate specificity
as well as spatially and temporally determined functions to the PP2A holoenzyme.
PP3, (also known as PP2B or calcineurin) is involved in numerous calcium-dependent
biological processes. It consists of a catalytic subunit (calcineurin A or CNA) and a regulatory
subunit (calcineurin B or CNB). CNA contains an N-terminal phosphatase domain, followed by
a CNB-binding helical domain, an autoinhibitory element, and a calcium (Ca2+)-calmodulinbinding domain. To date, three catalytic subunits (α, β, and γ) and two regulatory subunits (B1
and B2) have been identified (Wang et al, 2008). Calcineurin is inactive and only gains
phosphatase activity upon association with Ca2+-calmodulin. Calcineurin recognizes substrate
proteins through a consensus recognition motif of PxIxIT (P, proline) ( Bultynck et al., 2006;
Czirjak and Enyedi, 2006). Sequence variation within the PxIxIT motif results in a wide range of
binding affinities-between 0.5 and 250 µM-to calcineurin (Li et al., 2007).
Whereas, most PPP family members have isoforms encoded by different genes, protein
phosphatase 5 (PP5) is encoded by a single gene throughout Eukaryota. Another unique feature
of PP5 is that its regulatory and catalytic domains are all contained within the same polypeptide.
PP5 contains regulatory domain at its N terminus-the tetratricopeptide repeat (TPR), a known
protein-protein interaction motif (Shi, 2009). Similar to calcineurin (PP3 or PP2B), the
phosphatase activity of free PP5 is suppressed because the TPR domain and a C-terminal helix
αJ together maintain PP5 in an autoinhibitory conformation (Shi, 2009). The ability of the TPR
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domain to undergo a ligand-induced conformational change allows PP5 to respond to a number
of cellular factors and thus it may be crucial to PP5 function.
The structural information of other PSPs in the PPP family is not that clearly elucidated
to date as the four predominant members I have just discussed. However, some of them do share
considerable sequence similarity with those structurally characterized PSPs. For example, the
catalytic subunit of PP4 and PP6 are closely related to the catalytic subunit of PP2A/PP2. Both
PP4 and PP6 are believed to play an important role in diverse biological processes independent
of PP2A. The catalytic subunit of PP4 associates with its own regulatory subunits R1 and R2 to
form distinct complexes (Cohen et al., 2005) whereas the catalytic subunit of PP6 is thought to
form a heterotrimeric complex with a Sit4-associated protein (SAP) domain-containing scaffold
subunit and an ankyrin repeat subunit that likely serve as a regulatory subunit (Stefansson et al.,
2008).
In contrast to PP4 and PP6, PP7 appears to be unique to plants. Unlike other members in
PPP family, PP7 has three insertions in its phosphatase domain, and the recombinant PP7 only
gains its phosphatase activity by cleavage of its longest insertion, suggesting an autoinhibitory
role (Kutuzov et al., 1998).

I.3.2

The PPM family of protein phosphatases
Although the PPM family members (include PP2C and pyruvate dehydrogenase

phosphatase) are distantly related in primary sequence to PPP enzymes, their three-dimensional
structure and catalytic mechanisms appear to be quite similar. In sharp contrast with PPP
enzymes, in which the catalytic peptide interacts with a large number of distinct regulatory
subunits to carry out its specific function, PPMs are normally monomeric enzymes. And PP2C is
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insensitive to inhibition by okadaic acid (OA) or microcyctin-LR (MCLR) whereas OA inhibit
primarily the catalytic subunit of PP2A at an inhibitory constant of approximately 0.1 nM, which
is about 100 times potent than its inhibitory constant on PP1 (MacKintosh et al., 1990).
The myriad of functions performed by PPMs is possibly the result of the expression of a
large number of catalytic isoforms. For instance, at least 16 PP2C genes are found in humans and
probably more than 22 different polypeptides are produced through alternative splicing. The
primary function of PP2Cs appears to be the regulation of stress response, although it also plays
a role in cell differentiation, growth, survival, apoptosis, and metabolism (Lu and Wang, 2008).
Some PP2C members, such as PP2Cα, PP2Cβ, and PH domain leucine-rich repeat protein
phosphatase (PHLPP), are candidate tumor suppressor proteins, whereas others, such as PP2Cδ
(also known as Wip1), may contribute to oncogenic transformation (Shi, 2009).
The conserved catalytic core domain of human PP2C contains a central β sandwich, with
each β sheet flanked by a pair of α helices (Das et al., 1996). This arrangement generates a cleft
between the two β sheets, with the two metal ions located at the base of the cleft. Each metal ion
is hexa-coordinated by amino acid and water molecules. Three additional α helices, unique to
PP2C, associated with the core domain on one side and may contribute to substrate specificity or
regulation.
As mentioned above, unlike PPP family, PP2C has many different isoforms encoded by
different genes. These isoforms have distinct sequences and domain organizations, which also
exhibit distinct functions, expression patterns, and subcellular localization. How these isoforms
are regulated during signaling remains largely unknown. In addition to the conserved PP2C
phosphatase domain, PHLPP also contains an N-terminal PH domain and a leucine-rich repear
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(LRR) domain. How those additional domains may contribute to the phosphatase activity and
substrate specificity also remains unclear.

I.1

The FCP/SCP family and Chronophin
In contrast to all other protein Ser/Thr phosphatases discussed herein, members of

FCP/SCP family rely on the aspartic acid of the sequence motif DxDxT/V for phosphatase
activity. Another unusual feature of this family is that for a long time, there is only one primary
known substrate-the CTD of RNA polymerase II, which contains tandem repeat of the sequence
YSPTSPS.
The catalytic mechanism of Fcp1/Scp1 may involve two sequential steps (Ghosh et al.,
2008; Kamenski et al., 2004). First, an oxygen atom from the carboxyl group from the Nterminal aspartate in the DxDxT motif initiates a nucleophilic attack on the phosphorous atom of
a pSer, forming an acylphosphate intermediate. Second, a water nucleophile, likely activated by
the second aspartate in this motif, attacks the phosphorous atom in the intermediate, releasing the
inorganic phosphate. Mg2+ is thought to facilitate both steps by neutralizing the negative charges
of the phosphate group, which is different from that in PPP or PPM family, where the metal ions
are directly involved in catalysis through activation of a water nuelophile.
Chronophin, a member of the HAD family, is also an aspartate-based PSP (Gohla et al.,
2005). Like FCP/SCP, it contains the signature sequence motif DxDxT and a similar active site
(PDB code 2CFR). And it has only one known substrate protein. Chronophin dephosphorylates
pSer3 of cofilin, an important regulator of actin dynamics, leading to its activation.

18

I.4

Protein phosphatases: increasing importance noted in the regulation of TGFβ
signaling pathway
As mentioned in Section I.2, phosphorylation of type I receptor in the GS domain by type

II receptor upon binding of TGFβ superfamily ligand, and following phosphorylation of RSmads at their C-terminal SXS domain are key events in TGFβ signal cascade. The discovery of
the inhibitory linker region phosphorylation in R-Smads also adds one more essential regulatory
point to this signaling cascade. Taken together, kinase activity is essential in the activation of this
signaling cascade.
This notion also raises the investigation of protein phosphatases involved in this
conserved important signaling pathway since reversible phosphorylation is a well-established
essential regulatory mechanism in all living organisms.
Recent studies have identified several phosphatases that dephosphorylate Smads in the
nucleus and thus terminate the TGFβ/BMP signal. For example, the pyruvate dehydrogenase
phosphatase (PDP) and the small C-terminal domain phosphatases (SCPs) bind and
dephosphorylate the SSXS motif of mammalian and Drosophila Smad 1/5 (Chen et al., 2006;
Knockaert et al., 2006). The phosphatase PPM1A antagonizes both TGFβ and BMP signaling by
interacting with and dephosphorylating the C-terminus of all R-Smads (Duan et al., 2006; Lin et
al., 2006). Furthermore the SCPs can dephosphorylate the linker region of TGFβ/BMP R-Smads
(Sapkota et al., 2007; Sapkota et al., 2006; Wrighton et al., 2006), which has distinct outcomes
for TGFβ versus BMP signaling (activation and inhibition, respectively) ( Sapkota et al., 2006).
Smads are not only phosphorylated by type I receptor at the C-terminus, but also by a
plethora of kinases from cross-talking pathways, such as mitogen-activated protein kinases
(MAPKs), cyclin-dependent kinases (CDKs), Jun N-terminal kinases (JNKs) and glycogen
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synthase kinase 3 (GSK3) in the linker region. Interestingly, both the C-terminal and the linker
phosphorylation of Smads are induced upon stimulation with TGFβ and BMP (Sapkota et al.,
2006). The MAPK and GSK3 linker-phosphorylated Smad1 is recognized by the ubiquitin ligase
Smurf1, which not only targets the ubiquintnated Smad1 for degradation, but also inhibits its
binding to the nucleoporin Nup214. Thus, in order to be efficiently translocated into the nucleus,
the Smads have to overcome the inhibitory linker phosphorylation in cytoplasm. It is shown that
PP2A/PP2 regulates BMP signaling by interacting with BMP receptor complex and by
dephosphorylating both the C-terminus and the linker region. This dephosphorylation is mainly
at the linker region, therefore leading to increased nuclear localization and overall amplification
of this BMP signal (Bengtsson et al., 2009).
In vertebrates, different B subunits of PP2A demonstrate distinct roles in the regulation of
TGFβ/Activin/Nodal signaling: Bα enhances signaling by stabilizing the basal levels of type I
receptor, whereas Bδ negatively regulates these pathways by restricting receptor activity (Batut
et al., 2008). Dullard, preferentially complexes with the BMP type II receptor (BMPRII) and
partially colocalizes with the caveolin-1-positive compartment suggesting that it promotes
BMPRII degradation through the lipid raft-caveolar pathway (Satow et al., 2006). Dullard, which
contains a conserved catalytic phosphatase motif DxDxT/V (so Dullard is categorized to the
FCP/SCP family), also associates with BMPRI and represses the BMP-dependent
phosphorylation of BMPRI (Satow et al., 2006).
Despite the increasing data of the protein phosphatases characterized in the regulation of
TGFβ signaling pathway, investigators always ask whether there are more protein phosphatase
players in the regulation of this important pathway and if so, are those protein phosphatases
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identified or characterized show the same function in vivo since most data so far use mammalian
cell culture and not tested in an intact model organism.

I.5

TGF-β signaling pathway in C. elegans
In C. elegans, five TGF-β-related genes can be identified by sequence homology: daf-7,

dbl-1, unc-129, tig-2, and Y46E12BL.1. No biological roles have yet been described for tig-2 or
Y46E12BL.1. daf-7 is a TGF-β-related ligand and dbl-1 is more related to BMP2 and Dpp. Their
downstream signaling components have also been characterized, referred to as the Dauer
pathway and the Sma/Mab pathway (Figure 1.4), respectively (Suzuki et al. 1999; Gumienny and
Savage-Dunn. 2013).

Figure 1.5 Dauer pathway and Sma/Mab pathway in C. elegans (Gumienny
and Savage-Dunn, 2013)

I.5.1. The Dauer pathway
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Under unfavorable living conditions (high population density, low food availability, high
temperature), the worms will go into the dauer diapause as mentioned before. The dauer TGF-β
pathway is one signaling cascade that regulates this process. DAF-7 acts as the ligand (Ren et al.,
1996), which binds to type II receptor DAF-4 (Estevez et al., 1993) and type I receptor DAF-1
(Georgi et al., 1990). Upon ligand binding, DAF-1 phosphorylates R-Smad DAF-8 and DAF-14
(Riddle & Albert, 1997; Inoue & Thomas, 2000). Since DAF-14 does not have identifiable DNA
binding domains, it is unlikely to transduce signals directly into the nucleus whereas DAF-8 does
have DNA binding activity. Both DAF-8 and DAF-14 negatively regulate Co-Smad DAF-3
(Patterson et al. 1997), which associates with the Ski/SnoN homolog DAF-5 (da Graca et al.
2003) to form a transcription factor complex to control dauer entry (Liu et al. 2004). PDP-1,
homologous to human pyruvate dehydrogenase phosphatase (PDP), negatively regulates the
Insulin/IGF-1 signaling (IIS), therefore modulating dauer diapauses (Narasimhan et al., 2011).

I.5.2. Sma/Mab pathway
The Sma/Mab pathway was first characterized by Savage et al. in 1996 and regulates
body size and the development of male-specific sensory rays and copulatory spicules (Savage et
al., 1996). Mutants of components in this pathway have small body size (Sma) phenotype and
abnormal male tail (Mab) phenotype. The first three components in this pathway, sma-2, sma-3
and sma-4 were cloned by this group (Savage et al., 1996). Shortly after, other related
components are discovered. For instance, DBL-1 acts as the ligand (Suzuki et al., 1999) and
SMA-6 acts as the type I receptor (Krishna et al., 1999). They share the same type II receptor
DAF-4 with the Dauer pathway.
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Mutations in Sma/Mab pathway components cause the Sma phenotype. dbl-1 pathway
mutants show decreased seam cell length but normal seam cell nuclei number, suggesting that
decreases in cell size rather than cell number are responsible for dbl-1 mutant phenotype (Wang
et al., 2002). Organ size measurements have shown that different organs are reduced in size to
different degrees. The degree of reduction in the size of hypodermal seam cells and hyp7 is most
proportional to the degree of reduction in body size (Wang et al., 2002; Nagamatsu and Ohshima,
2004), consistent with the defined focus of action of Sma/Mab signaling components in the
hypodermis. Loss of dbl-1 activity results in smaller animals, while dbl-1 overexpression results
in longer animals, suggesting that dbl-1 acts as a dose-dependent regulator of body size (Morita
et al., 1999). In addition, comparison of the growth curves between the wild type and mutant
animals shows that the mutant animals have the same body size as wild type at the L1 stage.
However, the adult animals show only around 50% body size of the wild type (Savage-Dunn et
al., 2000), suggesting that a post-embryonic defect causes the Sma phenotype.
In addition to the Sma phenotype, a Mab phenotype is also found in these mutants. Male
tail sensory rays and spicules are essential for mating. Normally in wild type animals, there are
nine rays on each side of the male tail. However, dbl-1, daf-4, sma-2, sma-3, sma-4, and sma-6
mutant males show abnormal ray fusions and crumpled spicules. Ray fusion frequently occurs
between rays 4-5, 6-7, and 8-9 (Savage et al., 1996).
In addition to body size regulation and male tail development, the Sma/Mab pathway has
been shown to regulate innate immunity of C. elegans. sma-2, -3, -4 and -6 are required for
resistance to Pseudomonas aeruginosa. The loss of function mutants of those four genes are
hypersensitive to infection (Mallo et al., 2002). Liu’s lab shows mutations in the Schnurri
homolog sma-9 cause ventralization of the M lineage and that wild-type SMA-9 antagonizes the
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Sma/Mab TGFbeta pathway to promote dorsal M lineage fates (Foehr et al., 2006). More
recently, Murphy’s lab shows the involvement of Sma/Mab signaling in reproductive aging.
Reduction of Sma/Mab signaling delays reproductive aging by maintaining oocyte and germline
quality. Compared to cell-autonomous regulation of body size development, Sma/Mab signaling
regulates oocyte and distal germline quality maintenance nonautonomously and this process is
temporally and transcriptionally separable from its regulation of growth (Luo et al. 2009; Luo et
al. 2010).
To date, few other proteins are found to interact with Sma/Mab pathway components.
Padgett’s lab showed that LON-2 can negatively regulate Sma/Mab pathway activity. LON-2 is
a conserved member of the glypican family of heparan sulfate proteoglycans and can bind BMP2
in vitro. lon-2(lf) mutations result in a long body size phenotype and the Drosophila glypican
gene dally rescues the lon-2(lf) body size defect (Gumienny et al., 2007). More recently, the sole
member of the repulsive guidance molecule (RGM) family of proteins in C. elegans, DRAG-1, is
found to positively regulate Sma/Mab pathway activity at the ligand-receptor level (Tian et al.,
2010).
In my study, I screened a C. elegans RNA interference (RNAi) library of phosphatases to
identify genes that cause a body size phenotype. Since Sma/Mab pathway, a branch of TGFβ
signaling in C. elegans, regulates body size and male tail patterning); we propose that protein
phosphatases modulating this pathway might contribute to a body size phenotype upon being
knocked down by RNAi.
Combining epistatic analyses and reporter assays, 11 candidates were verified as protein
phosphatases by sequencing. These include homologs of mammalian PPM1A/B/G and PP1.
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Chapter II. Library-wide RNA interference screening to identify protein
phosphatases regulating Sma/Mab signaling pathway in C. elegans.
II.1 Abstract
RNA interference (RNAi), allows efficient analysis of endogenous gene function in
diverse organisms by introduction of double-stranded RNA (dsRNA) with corresponding
sequences. In Caenorhabditis elegans, it has been previously shown that RNAi can be performed
by directly microinjecting dsRNA into the adult hermaphrodite, by soaking the worms into a
solution of dsRNA, or by feeding the worms Escherichia coli expressing target-gene dsRNA.
Because of its ease to use, and high-throughput, the third mode of dsRNA introduction gains
more and more attention in large-scale screenings to identify genes involved in complex
biological processes.
Here we report a library-wide RNAi screen searching for protein phosphatases
modulating Sma/Mab pathway, a TGFβ signaling branch in Caenorhabditis elegans regulating
the body size and male tail patterning. Some of the methods described in this chapter have been
published (Liang et al., 2013). The candidates identified include homologues of mammalian
PPM1A/B/G and PP1.
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II.2 Introduction
Members of the transforming growth factor β (TGF-β) superfamily regulate a critical
array of cellular processes including cell proliferation, lineage determination, differentiation,
motility, adhesion, and death (Massague J. 1998). Signal transduction for this family is initiated
by formation of the active ligand-receptor complex between TGF-β ligand and two
transmembrane ser/thr kinase receptors, type I and type II receptor, and further transduced
through the intracellular Smad proteins. In response to TGFβ, receptor-activated Smads (RSmads) are phosphorylated at their C-terminal SXS motif by type I receptor (Feng and Derynck,
2005; ten Dijke and Hill, 2004). Phosphorylated R-Smads form complexes with common Smad
(Co-Smad), Smad4. Smad complexes then accumulate in the nucleus, where Smads regulate
downstream target gene expression with or without the cooperation of other specific transcription
cofactors.
Signal transduction pathways are often regulated by reversible phosphorylation, a
dynamic interplay between protein kinases and phosphatases. TGFβ ligand stimulation results in
Smad phosphorylation, inhibition of nuclear export, and persistent accumulation within the
nucleus (Schmierer and Hill, 2005), which implies the kinase activity is essential to maintain
TGFβ signaling cascade. Recent studies reveal the increasing importance of protein phosphatases
involved in the regulation of this canonical signaling cascade. A handful of protein phosphatases
have been identified. PPM1A/PP2Cα is shown to terminate TGFβ signaling by
dephosphorylating the C-terminal SXS motif of Smad2/3 (Lin et al., 2006) whereas the pyruvate
dehydrogenase phosphatase (PDP) and the small C-terminal domain phosphatases (SCPs)
modulate BMP signaling by dephosphorylating the SSXS motif of mammalian and Drosophila
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Smad 1/5 (Chen et al., 2006; Knockaert et al., 2006). Furthermore the SCPs can dephosphorylate
the linker region of TGFβ/BMP R-Smads (Sapkota et al., 2007; Sapkota et al., 2006; Wrighton et
al., 2006), which has distinct outcomes for TGFβ versus BMP signaling (activation and
inhibition, respectively) ( Sapkota et al., 2006). In vertebrates, different B subunits of PP2A
demonstrate distinct roles in the regulation of TGFβ/Activin/Nodal signaling: Bα enhances
signaling by stabilizing the basal levels of type I receptor, whereas Bδ negatively regulates these
pathways by restricting receptor activity (Batut et al., 2008). Bβ subunit interacts with both BMP
type I and II receptors and regulate the BMP signaling by dephosphorylating both the C-terminus
and linker region of Smad1 with the linker region as the preferred site, therefore leading to an
overall amplification of BMP signaling (Bengtsson et al., 2008). Dullard, which contains a
catalytic phosphatase motif DxDxT/V, also associates with BMPRI and represses the BMPdependent phosphorylation of BMPRI (Satow et al., 2006). The regulatory subunit of PP1,
GADD34 interacts with the catalytic subunit of PP1 to dephosphorylate TGFβI with or without
the assistance of inhibitory Smads, Smad6 or Smad7, attenuating the TGFβ signaling cascade
(Shi et al., 2004).
Despite the increasing number of protein phosphatases identified in the regulation of
TGFβ signaling pathways, how those protein phosphatases interact in vivo to modulate TGFβ
signaling pathways in diverse tissues and various biological processes and whether there are
novel players involved in this well-established simple core signal cascade still remain largely
unknown. Most screens reported did not adopt a model organism. Therefore, another major
concern is whether those phosphatases function in vivo as well as in vitro. The development of
RNA interference technique allow rapid and efficient analysis of gene function in large-scale
screens within a relatively simple classic genetic model, Caenorhabditis elegans, by simply
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feeding the worms Escherichia coli expressing target-gene dsRNA. This method is now widely
used to screen players involved in various biological processes such as neuronal specification
(Poole et al., 2011), stress response and longevity (Wang et al., 2010), and neuronal dysfunction
(Kuwahara et al., 2008).
In the nematode C. elegans, a BMP-related signaling pathway regulates body size and
patterning of sex-specific tissues of male posterior region (Patterson and Padgett, 2000;
Gumienny and Savage-Dunn, 2013). This pathway, which we refer to as the Sma/Mab pathway,
consists of ligand dbl-1 (Suzuki et al., 1999; Morita et al., 1999), type I receptor sma-6 (Krishna
et al. 1999), type II receptor daf-4 (Estevez et al., 1993), and Smads, sma-2, sma-3 and sma-4
(Savage et al., 1996). Mutations in any of these core pathway components cause small body size
(Sma) phenotype in both hermaphrodites and males, and a male abnormal (Mab) phenotype due
to transformations in male sensory ray identity and defective morphogenesis of the male
copulatory spicules.
Here we report a systematic RNAi screen for novel protein phosphatases modulating
Sma/Mab signaling in C. elegans. A C. elegans RNAi library of phosphatases including 168
clones was screened under an RNAi-hypersensitive mutant background, rrf-3, followed by
epistatic analyses and reporter assays. Eight likely candidates were found to regulate Sma/Mab
pathway directly or indirectly. These include homologues of mammalian PPM1A/B/G and PP1.
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II.3

Materials and methods

Strains and Caenorhabditis elegans protein phosphatase RNAi clones
C. elegans strains were cultured and maintained using standard methods at 20

unless

otherwise noted (Brenner, 1974). The following strains were used: N2 bristol (wild type), LG II:
rrf-3(pk1426), sma-6(e1482) (Brenner, 1974), sma-6(wk7) (Krishna et al., 1999); LG III: lin36(n766), sma-2(e502), sma-3(wk30); LG V: dbl-1(wk70); LG X: dbl-1(ctIs40), eri-1(mg366)IV;
lin-15B(n744)X, lon-2(e678).
LW2286 (lon-2(e678)X; jjls2277), LW2308 (dbl-1(wk70)V; jjls2277), and LW2436
(jjls2277) (gifts from Jun Kelly Liu, Cornell University) were used in RAD-SMAD reporter
assay.
Bacterial clones from the Caenorhabditis elegans phosphatase RNAi library (166 clones)
and two other RNAi clones containing Caenorhabditis elegans homologues of mammalian SCPs
were purchased from Source BioScience Life Science. All bacterial clones were grown on LB
agar plates supplemented with carbenicillin (25 µg/ml) and tetracycline (12.5 µg/ml) right before
use.
RNAi screen by feeding
Large-scale screen was carried out under an RNAi-hypersensitive mutant ground, rrf3(pk1426), using standard RNAi feeding protocol (Fraser et al., 2000; Kamath et al., 2003).
Minor modifications were made and described below.
Day1. A single bacterial colony of each RNAi clone was grown in 1 ml LB broth containing 100
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µg/ml of Ampicillin overnight at 37°C, ~280rpm. Bacteria carrying empty RNAi feeding vector
L4440 serves as control.
Day2. The 1ml over-night bacterial culture was transferred into 4 ml LB broth with 100 µg/ml of
Ampicillin and incubated at 37°C, ~280rpm for another 3-4 hours. Seed the fresh bacterial
culture onto EZ RNAi worm plates supplemented with carbenicillin (25 µg/ml) and IPTG (1
mM). Incubate at 37°C, overnight.
Day3. Transfer 10-12 L4 hermaphrodites into a corresponding RNAi bacterial plate obtained
from Day2. Incubate at 20°C, overnight until the worms reach young adult stage.
Day4. Transfer 10-12 young adult to a fresh corresponding RNAi bacterial plate. Let those
worms lay eggs for 4-5 hours. Then remove the mothers. Leave the RNAi plates with only eggs
at 20°C. Incubate for about 72 hours until the progeny reaches young adult stage.
Day7. Mount 35-40 adult worms to standard slides containing 2% Agarose pads. Then
photograph using QC Capture 2.73.0 software.
Analysis of body size measurements:
The body length of the resulting progeny was measured using Image-Pro Express
5.1.0.12 software. Student t-test was done to analyze the significance of the data (p<0.01).
Epistatic study
To investigate the interaction between the protein phosphatase candidates identified and
the known core components in Sma/Mab pathway, we carried out epistatic study in the following
mutant backgrounds: a strong loss-of-function type I receptor mutant (sma-6(wk7)), a weak loss30

of-function type I receptor mutant (sma-6(e1482)), a loss-of-function mutant in a negative
regulator of this Sma/Mab pathway (lon-2), and in a strain that over-expresses the TGFβ ligand,
DBL-1 (dbl-1++).
First, the mutant worms were fed on appropriate protein phosphatase RNAi clones as
described in RNAi screen part. The resulting 72 hour-old progeny were photographed and the
body length was analyzed
RAD-SMAD reporter assay
To determine whether the protein phosphatase candidates identified regulate body size
dependent of or independent of Sma/Mab pathway, RAD-SMAD reporter assays were carried
out (Tian et al., 2010).
Briefly, 10-12 L4 animals were transferred to feeding plates seeded with appropriate
protein phosphatase RNAi clones, incubated overnight, and transferred to fresh feeding plates to
lay eggs for 4 hours. The synchronized progeny were scored at L2 stage when the expression of
RAD-SMAD reporter in hypodermis becomes predominant.
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II.4 Results
II.4.1 Comparative analysis of RNAi with wild type and different RNAi-hypersensitive
mutant strains
First, I determined which RNAi-hypersensitive mutant background is suitable for largescale RNAi screen. To make the result of an RNAi screen reliable, the starting strain used must
be sensitive to RNAi and the experiments carried out under this genetic background must show
consistent pattern. Since we screen for a body size phenotype, the brood size should be large
enough so that we can obtain enough samples for further analyses. To validate the RNAi effect, I
first conducted a trial experiment using two RNAi-hypersensitive mutant stains: eri-1(mg366)IV;
lin-15B(n744)X, and rrf-3(pk1426), as well as lin-36(n766), a component in the lin-15 pathway
whose RNAi sensitivity is nevertheless similar to N2 (Simmer et al., 2002). I knocked down
known components in Sma/Mab pathway: dbl-1/ligand; sma-2, sma-3, sma-4/Smads; and sma6/receptor in all three mutant backgrounds (Figure 2.1). All tested strains were small when dbl-1,
sma-2, sma-3, sma-4 were knocked down by RNAi. Whereas, lin-36 exhibited a significant body
length increase upon sma-6 RNAi, which is opposite to sma-6(lf) mutant phenotype. These
results suggest that lin-36 might modulate body size independent of Sma/Mab pathway and can
not be used as an RNAi-hypersensitive strain in our RNAi screen.
Upon sma-3 RNAi, both wild type (N2) and all three mutant strains show a significant
body length decrease, which is consistent with the Sma phenotype exhibited by sma-3(lf) genetic
mutants. Whereas, the % body length decrease in the N2 background (~10%) is much less than
that under RNAi-hypersensitive mutant backgrounds (~15% in rrf-3 background and ~24% in
eri-1(mg366)IV; lin-15B(n744)X background, respectively) (Figure 2.1). These data confirmed
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that RNAi-hypersensitive mutants are more sensitive than wild type when screening for body
size phenotype.
Though our data indicates that eri-1(mg366)IV; lin-15B(n744)X demonstrates the
strongest phenotype upon RNAi, the animals did not grow well and produced less progeny.
Therefore in large-scale screen, I would not get enough worms for further analysis. As a result,
we favor the rrf-3 strain to be the primary mutant background to be used in a large-scale RNAi
screen to identify novel protein phosphatases that regulate C. elegans body size.

Figure 2.1 All three RNAi-hypersensitive mutants tested show body size
phenotype upon core Sma/Mab pathway components RNAi. All data were
analyzed using student t-test. Error Bar: standard error. *: P<0.01. N (worms
scored per RNAi treatment per experiment): ≥30.
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II.4.2 Large-scale RNAi sceen using rrf-3 identified novel players involved in body size
control
As discussed in Chapter I, Sma/Mab pathway is one of the major pathways regulating
Caenorhabditis elegans body size. Novel components involved in this pathway and new
modifiers modulating the Sma/Mab pathway might affect the body size as well. Based on this
hypothesis, I first conducted a pilot screen using rrf-3 mutants. The starting RNAi liabrary used
in this study includes bacterial clones from the Caenorhabditis elegans phosphatase RNAi
library (166 clones) and two other RNAi clones containing Caenorhabditis elegans homologues
of mammalian SCPs were purchased from Source BioScience Life Science. After RNAi, I found
that 124 clones contributed to a body size phenotype at 72hrs (Figure 2.2). Among them, 107
resulted in the Lon phenotype whereas 17 led to the Sma phenotype. Though I was focusing on
candidates that resulted in body size phenotype upon RNAi treatment, I also noticed that several
RNAi clones led to other developmental defects such as Emb (embryonic lethal), or Mor
(morphological abnormality such as protruded vulva) were also identified (as summarized in
Table 2.1). These data suggest that our screening protocol can also be used to sceen other
developmental phenotypes than the body size phenotype.
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Figure 2.2 A large-scale RNAi screen using rrf-3 mutants has identified RNAi
clones contributing to body size phenotype. rrf-3 worms were fed with RNAi
clones from the C. elegans protein phosphatase RNAi library as described in part II.3
and the resulting progeny were scored at the young adult stage (72hrs after egg
collection). Lon: long body size; NS: no detectable phenotypic change; Sma: small
body size; Emb: embryonic lethal; Mor: morphological abnormality, such as
protruded vulva; Sma/Mab: known components of Sma/Mab pathway.

I then carried out in silico analyses to categorize the protein phosphatase candidates using
wormbase annotation (http://www.wormbase.org). Among the 107 RNAi clones contributing to
the Lon phenotype, 48 belong to the protein tyrosine phosphatase family; 30 are putative
members of protein serine/threonine phosphatase family; 1 belongs to the Dual Specificity
Protein Phosphatase (DUSP) family; 1 is identified as intestinal acid phosphatase (pho-5); 12 are
not annotated as any protein phosphatases, the function of the rest 15 are unclear (as summarized
in Table 2.2).
Table 2.1 The RNAi clones cause developmental defects other than body size
phenotype in rrf-3 mutant background
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Phenotype
upon RNAi
Emb

Mor

Gene idenfier
F26B1.3
F38H4.9
F42G8.8
F44F4.2
F48E8.5
K07F5.6
Y48G1A_54.b
F22D6.9
F26E4.1
F32E10.4
K02A11.1
K09F6.3
R03D7.8
T15B7.2

Gene function
ima-2, importin-a, nuclear transport factor
let-92, protein serine/threonine phosphatase
Protein serine/threonine phosphatase
Protein tyrosine phosphatase
paa-1, PP2A A subunit
Protein tyrosine phosphatase
unknown function
Protein serine/threonine phosphatase
Protein serine/threonine phosphatase
ima-3, importin-a, nuclear transport factor
PP1 regulatory subunit
Protein tyrosine phosphatase
PP1 catalytic domain-like
Protein tyrosine phosphatase

Table 2.2 Classification of protein phosphatase candidates that contribute to Lon
body size phenotype upon RNAi in rrf-3 background
Protein categories
Protein tyrosine phosphatase

Gene identifier
B0244.2
C05B10.1
C07E3.4
C16A3.2
C17H12.3
C17H12.5
C18E9.7
C24D10.1
C33F10.8
C33H5.16
C43E11.5
C46A5.1
F08B1.1
F20H11.4
F25H5.7
F26A3.4
F36H1.3
F36H12.10
F38H4.4
F44G4.8
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F47B3.2
F54C8.4
F55F8.7
F57H12.5
H06O01.4
K03H1.8
K04D7.4
K07F5.8
M04G7.2
M05D6.3
R06B10.1
R12E2.10
R155.3
T04F3.3
T20B6.1
T21E3.1
T22C1.8
T27A3.5
T28F4.3
VW02B12L.2
W01B6.6
Y5F2A.3
Y116A8C.37
ZK354.8
ZK484.7
ZK757.2
ZK783.2
ZK809.1
Protein serine/threonine phosphatase
C05A2.1
C06A1.3
C06G1.5
C13G3.3
C30A5.4
C34C12.3
C34D4.2
C43E11.6
C47A4.3
F23B12.1
F23H11.8
Protein serine/threonine phosphatase F25B3.4
(cont.)
F44B9.9
F49E11.7
F52H3.6
F58G1.3
M04C9.6
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Acid phosphatase
Dual specificity protein phosphatase
Not annotated as protein phosphatase

Function unknown

R08C7.8
T03F1.5
T16G12.7
W03D8.2
W09C3.6
W09D10.4
Y40H4A.2
Y69E1A.4
ZC477.2
ZC477.3
ZK354.9
ZK938.1
ZK945.8
B0361.7
C24F3.2
C12D8.10
F41F3.2
F43C1.1
F53B2.5
R06B10.2
R09E10.2
R10F2.6
R31.2
R107.8
T06D8.3
T19B10.7
ZC518.3
B0478.2
C25A1.9
CC8.c
F08F3.5
F38E9.3
H02F09.4
H06I04.d
R10E4.9
R17.2
Y18H1A_68.a
Y32H12A.e
Y39B6B.ff
Y62E10A.m
Y110A7A.p
Y119D3_464.f
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Among the 17 protein phosphatase candidates that led to a Sma phenotype in the rrf-3
mutant background upon RNAi, 13 were annotated as protein serine/threonine phosphatase; 1
belongs to the protein tyrosine phosphatase family; 1 was identified as importin-b (imb-6); the
function of the remaining 2 candidates is yet not clear (as summarized in table 2.3). Taken
together, we identified novel players involved in body size control, via a large-scale RNAi screen
using rrf-3.

Table 2.3 Classification of protein phosphatase candidates that contribute to Sma
body size phenotype upon RNAi in rrf-3 background
Protein categories
Protein tyrosine phosphatase
Protein serine/threonine phosphatase

Nuclear transport factor
Function unknown

Gene identifier
C49A11.5
B0379.4
B0511.7
C02F4.2
C09H5.7
C27B7.6
C33H5.8
C42C1.2
F20D6.6
F25D1.1
F28C6.8
F45E12.1
T19C3.8
T23F11.1
C49H3.10
Y39B6B.e
Y41D4A_3192.b

We also noticed that there were some variable results among individual RNAi treatments,
which is consistent with the data reported by other laboratories (Simmer et al., 2003). The
variable results obtained from individual RNAi treatments were due to the high frequency of
false negatives present in each RNAi screen. To minimize the variability issue, we then carried
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out a secondary library-wide screen in a sma-6(wk7) mutant background, which will be discussed
in the following part (II.4.3). A few variable results are shown in Table 2.4.

Table 2.4 Variable RNAi effects
Gene
identifier
C06A1.3
C42C1.2
W09C3.6

Gene function
Protein Ser/Thr
phosphatase
PP2C-like
Protein Ser/Thr
phosphatase

1st rrf-3 screen
% control
P value
114.19±4.55
3.02E-19

2nd rrf-3 screen
% control
P value
91.57±2.88 1.03E-11

89.89±4.96
108.75±4.00

98.18±3.73
96.65±4.31

9.03E-12
1.23E-11

0.07
4.00E-03

II.4.3 RNAi screen in sma-6(wk7) background reveals potential modifiers regulating
Sma/Mab pathway
When a novel player is identified, it is important to determine the interactions with other
known mutants of the same phenotype. This is refered to an epistatic analysis. By doing this, one
can determine that the new component acts in an existing pathway or in a novel pathway for its
function. If two separate mutations result in the reduced body length as compared to each
mutation alone, this is interpreted as parallel pathway. The homozygous double mutants should
be smaller than either single mutant alone, indicating that two mutations have additive effects. If
one mutation results in long body size by affecting one pathway, while a second mutation causes
small body size affecting another pathway, the double mutant will show additive effect with
intermediate body size (Morck et al., 2006) (Figure 2.3).

40

Figure 2.3 Genetic interactions between mutants (Figure generated by
Fernando)
In our study, it is not practical to make double mutants of all candidates identified with
the known components in the Sma/Mab pathway. However, upon RNAi in a single mutant
background, we can mimic the phenotype of double mutants, therefore we can get clues of how
these candidates interact with the Sma/Mab pathway to regulate the body size in a relatively
short time.

II.4.3.1. Knocking down known components in Sma/Mab pathway indicates the basal
activity of this pathway in the absence of ligand activation
I first carried out experiments to test how the known components in Sma/Mab pathway
act in the sma-6(wk7) background, a strong loss-of-function allele of the type I receptor, SMA-6.
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As is consistent with our expectation, when we knocked the ligand DBL-1 and the type I
receptor SMA-6, the RNAi worms exhibited the similar Sma phenotype as sma-6(wk7) mutant
(p>0.01). In contrast, when we knocked down the expression of SMAs: sma-2, and sma-4, the
RNAi worms show enhanced Sma phenotype (p<0.01) (Figure 2.4). This suggests that without
ligand activation, there is basal activity of Sma/Mab pathway which partially promotes growth of
Caenorhabditis elegans. Whereas when another SMA protein, SMA-3, is downregulated by
RNAi, we noticed a similar sma-6(wk7) mutant phenotype.
In a previous study done in our lab, Liang et al. identified SMA-9, a Drosophila Schnurri
homologue, which acts as a transcriptional cofactor to regulate a subset of Sma/Mab pathway
targets. Therefore, we also included an RNAi clone of sma-9 in this study. Upon sma-9 RNAi,
the resulting progeny displayed a similar phenotype as that of the sma-6(wk7) mutants.
Taken together, we demonstrated even without ligand activation, there is basal activity of
Sma/Mab pathway to promote growth. Our data suggest that this basal activity requires the
presence of two intact SMAs, SMA-2 and SMA-4.
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Figure 2.4 Basal activity of the Sma/Mab pathway in the absence of ligand
activation. Control: sma-6(wk7) worms were fed on bacteria containing only RNAi
feeding vector, L4440. Data were then analyzed using student t-test. Error bar:
standard error. *: p<0.01. N (worm scored per RNAi treatment per experiment) ≥30.

II.4.3.2. Comparative analyses of rrf-3 and sma-6(wk7) screening data reveals potential
modifiers regulating Sma/Mab pathway
As mentioned in section II.4.2, a primary screen carried out in the rrf-3 RNAi –
hypersensitive background, identified a plenty of candidates regulating body size in
Caenorhabditis elegans. One of our major concerns is that due to the high frequency of false
negatives identified in each RNAi screen, we might have obtained some false positive candidates.
So our next goal was to determine whether the candidates were involved in the regulation of
Sma/Mab pathway or acted as direct components in this signal cascade. Towards this end, I then
screened the whole Caenorhabditis elegans protein phosphatase RNAi library in the sma-6(wk7)
background.
I analyzed RNAi phenotypes in the sma-6(wk7) background. 64 out of the 107 RNAi
clones that led to the Lon phenotype in the rrf-3 background upon RNAi, exhibited the sma-6(lf)
mutant phenotype or suppressed the Sma phenotype in the sma-6(wk7) background (Figure 2.5).
There was one RNAi clone that suppressed the Sma phenotype only in the sma-6(wk7)
background, but exhibited no body size phenotype in the rrf-3 mutant background upon RNAi.
In contrast, 12 RNAi clones identified in the primary rrf-3 screen as potential positive regulators
of body size showed no body size change or enhanced Sma phenotype in the sma-6(wk7)
background (Figure 2.5). Three RNAi clones resulted in a similar phenotype as that of the sma-

43

6(lf) mutants, or the enhanced Sma phenotype, whereas had no effect on body size of rrf-3
animals in the primary screen, when knocked down by RNAi (Figure 2.5).

Figure 2.5 Comparative analysis using rrf-3 and sma-6(wk7) data revealed
potential candidates modulating body size in a Sma/Mab pathway-dependent
manner. Left panel: shows the 64 potential negative regulators; Right panel:
indicates that the 12 RNAi clones might control body size via positively regulating
the Sma/Mab pathway.
: RNAi clones that exhibited expected body size
phenotype were identified in rrf-3 screen;
: RNAi clones identified in sma6(wk7) screen showed expected body size phenotype.

In addition to the body size phenotype, we also noticed other developmental defects
while tesing the RNAi clones in sma-6(wk7) mutants. 5 out of 6 RNAi clones cause Emb
phenotype in both rrf-3 and sma-6(wk7) backgrounds. One RNAi clone displayed the Mor
phenotype in sma-6(wk7) mutants but not in rrf-3 worms. However, we did not observe the same
Mor phenotype for any of the RNAi clones, as visualized in the rrf-3 background (Table 2.5).
The phenotypic differences found between the two genetic mutants might partially be explained
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by the hypersensitivity to RNAi in the rrf-3 background, since the sma-6 strain assayed did not
contain the rrf-3 mutation.

Table 2.5 RNAi clones cause developmental defects other than body size
phenotype in sma-6(wk7) mutant background
Phenotype
upon RNAi
Emb

Mor

Gene idenfier
F26B1.3
F38H4.9
F44F4.2
F48E8.5
Y48G1A_54.b
F08B1.1

Gene function
ima-2, importin-a, nuclear transport factor
let-92, protein serine/threonine phosphatase
Protein tyrosine phosphatase
paa-1, PP2A A subunit
unknown function
Protein tyrosine phosphatase, vhp-1

II.4.4 Epistatic analyses using dbl-1(ctls40) and lon-2(e678) further eliminate candidates
not involved in regulation of Sma/Mab pathway.
As discussed in section II.4.3, by comparative analysis using rrf-3 and sma-6(wk7)
screening data, we narrowed the candidate pool to 80. I then carried out RNAi experiments using
dbl-1(ctls40) and lon-2(e678) backgrounds. The dbl-1(ctls40) worm strain carries an integrated
array overexpressing the ligand DBL-1. Therefore, Sma/Mab pathway is hyperactivated,
resulting in a Lon phenotype (Figure 2.6). LON-2 is a conserved member of the glypican family
of heparin sulfate proteoglycans and negatively regulate Sma/Mab pathway by attenuating the
ligand-receptor interaction (Gumienny et al., 2007). lon-2 mutant therefore exhibits a Lon
phenotype (Figure 2.6).
If the protein candidates positively regulate Sma/Mab pathway, upon RNAi, the resulting
worms would show the dbl-1(ctls40) or lon-2(e678) mutant phenotype or suppress the Lon
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phenotype. Whereas, if the protein candidates modulate Sma/Mab pathway negatively, the RNAi
worms would show the dbl-1(ctls40) or lon-2(e678) mutant phenotype or enhance the Lon
phenotype.
I then compared the dbl-1(ctls40) and lon-2(e678) data with the previous screening data
using rrf-3 and sma-6(wk7). Based on the data comparison, we narrowed the 80-candidate pool
to 69. Taken together, our epistatic analyses showed that the candidate genes identified interact
with known components in the Sma/Mab pathway. The epistatic data helped to eliminate some
false positives. However, we do not have enough clues to put any single candidate into a precise
position in the Sma/Mab pathway yet.
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Figure 2.6 Representive figures show the body size phenotype scored in dbl1(ctIs40) and lon-2(e678) backgrounds, respectively. Panel A, E: dbl-1(ctIs40)
worms fed on control RNAi show a Lon phenotype; Panel B: Upon C27B7.6 (a
protein Ser/Thr phosphatase) RNAi, dbl-1(ctIs40) exhibited a Suppressed Lon
phenotype; Panel F: Upon H02F09.4 (a transposon in origin) RNAi, dbl-1(ctIs40)
exhibited an Enhanced Lon phenotype; Panel C, G: lon-2(e678) worms show a Lon
phenotype upon control RNAi; Panel D: Upon ppm-1 RNAi, lon-2(e678) worms
show a Suppressed Lon phenotype; Panel H: Upon R155.3 (a protein tyrosine
phosphatase) RNAi, lon-2(e678) worms show an Enhanced Lon phenotype.

II.4.5 RAD-SMAD reporter assay identified candidates regulating Sma/Mab pathway.
The epistatic study described in section II.4.3 and II.4.4 suggested that we had identified
protein phosphatase candidates that regulate Sma/Mab pathway activity to maintain the normal
body size of worms. To test this hypothesis, one can demonstrate the direct protein-protein
interaction by biochemical assays such as western blot and immunoprecipitation. However, as
there are no existing worm specific phospho-SMAD antibodies or anti-SMAD antibodies, it is
hard to carry out such experiments. I aligned the primary sequences of SMA proteins with
human SMAD proteins, and selected a phospho-SMAD antibody and pan-SMAD antibody
binding to the most conserved epitopes. Then I performed immunostaining experiments and
western blot analyses. Not one worked, in contrast, when I blotted the same blot with anti-tubulin
antibody, I visualized the expected band (data not shown). In short, we cannot use biochemical
assays to demonstrate the direct candidate-SMAs interaction due to the lack of available SMAspecific antibodies.
An alternative mothod to monitor the direct output of Sma/Mab pathway is to use
Sma/Mab-responsive reporters. I used the RAD-SMAD reporter (a kind gift fromDr. Jun Kelly
Liu, Cornell University) in this study. The RAD-SMAD reporter contains multiple copies of the
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SMAD boxes (or SMAD binding site GTCT) organized in the most affinite RLR orientation
upstream of the minimal pes-10 promoter and gfp (Tian et al., 2010, Figure 2.7). The expression
level of the RAD-SMAD reporter appeared rather dynamic during development, with stronger
intestinal expression in embryos and L1s, but fainter in adults and stronger hypodermal
expression in L2s and L3s. So we decided to check the reporter activity in the L2 stage upon
candidate RNAi depletion.
We proposed that if the candidates regulate body size via the Sma/Mab pathway, the
reporter activity would change, upon candidate RNAi depletion. If the candidates positively
modulate the Sma/Mab pathway, we would observe weaker expression of RAD-SMAD reporter
when these candidates are depleted by RNAi. In contrast, a stronger reporter activity suggests
that the candidates tested are negative modifiers of this pathway (Figure 2.7).
I compared the results of reporter assay with the previous screening data and epistatic
studies, 22 candidates were identified as the most likely protein phosphatase regulating the
Sma/Mab pathway.
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Figure 2.7 RAD-SMAD reporter expression upon candidate RNAi. Panel A:
Scheme of the RAD-SMAD reporter construct. The oligo sequence shown here above
is designed as Sma/Mab-responsive element (Tian et al., 2010). Panel B, C, D: RADSMAD reporter expression upon RNAi. Worm strain used: LW2436 (jjls2277). All
RNAi worms were scored at L2 stage. B: Upon control RNAi, hypodermic nuclear
expression of gfp is clearly visualized. C: Upon ppm-1 RNAi, the gfp expression is
decreased significantly. D: Upon R155.3 RNAi, the gfp expression is upregulated.
II.4.6 Homologues of mammalian PPM1A/B/G and PP1 are identified and verified by
sequencing analysis.
As mentioned in section II.4.5, 22 candidates were identified as potential protein
phosphatase regulators of the Sma/Mab pathway. We then sent out those RNAi clones for
sequencing (as described in materials and methods).
I analyzed the sequencing data by blasting the sequences within the Caenorhabditis
elegans genome (open database from wormbase.org). 5 out of the 22 candidates did not match
any sequence within the whole database (data not shown). 11 are identified as protein
phosphatases. One is identified as a member of sri-family chemoreceptor. Another one is
annotated as a transposon. The remainders had no known functions (as summarized in Table 2.6).
The sequence verified candidates showed a consistent pattern in primary rrf-3 screen, epistatic
analyses, and the following RAD-SMAD reporter assay (the phenotypes of the protein
phosphatase candidates are summarized in Table 2.7).

Table 2.6 Eight RNAi clones are identified as protein phosphatases by sequencing
Protein category
Chemoreceptor
Transposon
Protein phosphatase

Gene identifier
B0454.2
H02F09.4
C06A1.3
C42C1.2
C43E11.5

Gene function
7 TM chemoreceptor, sri-family, sri-31
WBTransposon 00000686
Protein serine/threonine phosphatase
Protein phosphatase
Protein tyrosine phosphatase*
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Unknown function

F25D1.1
F38H4.4
F44B9.9
R155.3
VW02B12L.2
W09C3.6
Y32H12A.4
ZK783.2
C47A4.1
F41H10.4
T06D8.3
ZK945.8

Protein serine/threonine phosphatase, ppm-1
Protein tyrosine phosphatase
Protein phosphatase
Protein tyrosine phosphatase*
Protein tyrosine phosphatase*
PP1, gsp-3
PP1 regulatory (inhibitory) subunit 2
Protein tyrosine phosphatase, upp-1
Unknown
Unknown
Unknown
Unknown

.
*: The latest Wormbase release annotates that those genes show protein tyrosine
phosphatase activity.
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Table 2.7 The candidates identified and sequence verified exhibit a consistent pattern in primary rrf-3 screen, epistatic
analyses, and RAD-SMAD reporter assay
Functional

Gene

Category
PSP

identifier
C06A1.3
F25D1.1
W09C3.6
Y32H12A.4
C42C1.2
F44B9.9
C43E11.5
F38H4.4
R155.3
VW02B12L.2
ZK783.2

PSP-like
PTP

Body size phenotype
rrf-3
Lon
Sma
Lon
Lon
Sma
Lon
Lon
Lon
Lon
Lon
Lon

sma-6(wk7)
NS
NS
Lon
NS
NS
NS
NS
NS
NS
NS
NS

sma-6(e1482)
ND
NS
ND
ND
ND
ND
ND
NS
NS
ND
ND

dbl-1(ctIs40)
Lon
NS Text
NS
NS
NS
Lon
NS
NS
Lon
Lon
Lon

RAD-SMAD reporter activity
lon-2(e678)
Lon
Sma
Sma
Lon
Sma
NS
NS
NS
Lon
NS
Lon

Stronger
Weaker
Weaker
Stronger
NS
Weaker*
Stronger
Stronger
Stronger
Stronger
Stronger

Lon: long body size; NS: No significant change compared with control RNAi; ND: Not done; Sma: small body size.
*: though show a change in expression level, not agree with other data.
All body size data were analyzed using student t-test, p<0.01.
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II.5

Discussion

II.5.1 rrf-3 hypersensitive mutant is highly efficient for large-scale RNAi screen
rrf-3 encodes an RNA-directed RNA polymerase (RdRP) homolog that inhibits somatic
RNAi, and thus promotes activity of repeated genes such as multicopy transgenic array.The
effect of RRF-3 on RNAi is opposite to that of RRF-1 (which stimulates somatic RNAi). This
might arise from the competition by RRF-3 with RRF-1 or EGO-1 in RNAi formation. rrf-3
mutants are hypersensitive to somatic RNAi, which makes rrf-3 a desirable starting strain in
various large-scale or genome-wide screens (Simmer et al., 2003).
In our study, we demonstrated that rrf-3 mutants are more suitable to screen for novel
players involved in body size control. First, when known components of Sma/Mab pathway are
depleted by RNAi, rrf-3 worms show the same Sma phenotype as the known genetic loss-offunction mutants in this pathway. Second, the body length decrease in rrf-3 background is more
significant than that in wild type, which increases the sensitivity of the RNAi treatment and
enlarges the potential candidate pool. Third, because we need to analyze the body size phenotype
of RNAi worms using epistatic analyses, it is important to obtain enough worms for analysis.
Though we noticed that eri-1;lin-15B worms were more sensitive to RNAi, the small brood size
and decrease in viability limited its usage in such kind of screens.
Due to the high frequency of false negatives existed in each RNAi sceen, we cannot rule
out the possibility that some candidates tested are missing in the primary rrf-3 screen. And since
body size control involves multiple signal pathways, some modifiers might synergize to exert
their effect. Therefore, depletion of a single gene probably cannot result in a detectable
phenotypic change. Thus in our screen, we might have missed such kind of candidates.
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II.5.2 Novel protein phosphatases regulating Sma/Mab pathway are identified
To date, existing evidence has proven the involvement of protein phosphatases in the
regulation of TGFβ pathway. Some examples are PPM1A, PDP, SCPs, PP2A, Dullard, and PP1
(Lin et al., 2006; Chen et al., 2006; Knockaert et al., 2006; Sapkota et al., 2007; Wrighton et al.,
2006; Batut et al., 2008; Bengtsson et al., 2008; Satow et al., 2006; Shi et al., 2004). These data
contribute to elucidate the regulatory mechanism of TGFβ pathway and in some degree explain
why this simple signal cascade can regulate a plethora of developmental processes, leading to
distinct outcomes in specific cell types.
However, to our knowledge, no one has carried out large-scale screen in a model system
to identify novel protein phosphatases involved in this conserved pathway. Whereas, the body of
literature suggests that the regulation by protein phosphatases can occur at any level of that
signaling pathway, which implies that more protein phosphatases might be involved. That is why
we carried out the large-scale screen in Caenorhabditis elegans.
There are two branches of the TGFβ pathway within Caenorhabditis elegans, the Dauer
pathway and the Sma/Mab pathway. The former controls the entrance and exit of dauer stage, a
developmental stage equivalent to L3 stage that responds to stress such as food scarcity (Hu,
2007). The latter is required for normal body size and male tail patterning. We proposed that if a
protein phosphatase regulates the Sma/Mab pathway, it will contribute to a body size phenotype
upon RNAi. If they function in the dauer pathway, we might have observed a dauer-constutive
phenotype at 20°C. During our primary rrf-3 screen, we did not notice any treatments that
resulted in the dauer-constitutive phenotype, thus we focused on the body size phenotype.
I then carried out an epistatic analysis in different genetic backgrounds of known
components of Sma/Mab pathway. The epistatic data combined with RAD-SMAD reporter assay
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results revealed a few protein phosphatase candidates that modulate this pathway. As shown in
section II.4.6, we verified 11 out of 22 candidates as protein phosphatase by sequencing.
In summary, we conducted a large-scale RNAi screen by feeding the Caenorhabditis
elegans with the ds-RNA expressing bacteria. We also demonstrated that the candidates
genetically interact with known components in the Sma/Mab pathway by epistatic analyses. The
RAD-SMAD reporter assay further identified candidates involved in the regulation of the
Sma/Mab pathway. We then verified our results by sequencing. Our screening strategy proved to
be successful in revealing novel players involved in the regulation of the Sma/Mab pathway.
And this screening strategy can also be modified to search for novel players in other signal
pathways.
Among the protein phosphatases identified, we found homologs of mammalian
PPM1A/B/G and PP1, which is consistent with previous reports. We also found other three
protein serine/threonine phosphatases involved in the regulation of the Sma/Mab pathway. As
the TGFβ pathway is conserved among species, our study might shed light on the elucidation of
its regulatory mechanisms.
To our surprise, our data revealed that members of the protein tyrosine phosphatase
family also modulate the Sma/Mab pathway. One possible explanation is that the tyrosine
phosphatases might exert their effects by acting on kinases that modify the linker region of
receptor-SMAs, therefore regulating Sma/Mab pathway indirecty. Another possibility is that the
protein tyrosine phosphatases might act indirectly through crosstalk with other signaling
pathways. We also cannot rule out the possibility that there are some unknown components
within this pathway serving as direct substrates of those protein tyrosine phosphatases.
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II.5.3 Players other than protein phosphatases are identified to modify the Sma/Mab
pathway activity
Though we started our RNAi screen using a Caenorhabditis elegans protein phosphatase
RNAi liarary, we found some of the genes assigned to the library are not real protein
phosphatases. For example, we identified sri-31 as a novel modulator in the Sma/Mab pathway.
sri-31 encodes an ortholog of class I serpentine receptor (or guanine nucleotide-binding protein
coupled receptor). It transduces an extracellular signal through interaction with a guanine
nucleotide-binding (G) protein and adopts a framework comprising seven transmembrane(TM)
helices. Another candidate was H02F09.4, which is annotated as a transposon and believed to
have no phosphatase activity.
In short, our screening data and further experiments to characterize the protein
phosphatases might supplement or curate the existing information of Caenorhabditis elegans
genome dataset, therefore providing the investigators some more reliable source to facilitate their
study.
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Chapter III.

PPM-1 (Protein Phosphatase Magnesium2+/manganese2+-

dependent-1) regulates body size by modulating Sma/Mab pathway activity

III.1 Abstract
Background: The transforming growth factor β (TGFβ) signaling cascade activates diverse
cellular responses in normal development events in metazoans. It has also been shown to be
involved in the pathogenesis of many human diseases. Reversible phosphorylation is a hot spot
to investigate in the last decades, which has proven to be an essential regulatory mechanism to
modulate the TGFβ signaling pathway. In Caenorhabditis elegans, a conserved TGFβ pathway,
the Sma/Mab pathway, controls body size and male tail patterning. To identify and characterize
novel protein phosphatases involved in this pathway, we carried out a library-wide RNAi screen
using Caenorhabditis elegans as a model system followed by genetic and molecular biological
studies.
Results:

Several

lines

of

evidence

indicate

that

the

protein

phosphatase

magnesium2+/manganese2+-dependent-1 (PPM-1) plays a role as a positive regulator of the
Sma/Mab pathway in body size control. Epistatic analyses placed it downstream of the DBL-1
ligand and its type I receptors.
Conclusion: The PPM-1 protein regulates Caenorhabditis elegans body size in a manner
dependent on the Sma/Mab pathway.
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III.2 Introduction
The transforming growth factor β (TGFβ) superfamily comprises a large number of
secreted peptide growth factors: the TGFβ/Activin/Nodal/growth and differentiation factors
(GDF) subfamily, and the bone morphogenetic proteins (BMPs) subfamily (Massague and Chen,
2000

Roberts and Sporn, 1993). Members of this superfamily activate a broad range of cellular

responses in metazoans, such as cell growth, differentiation, extracellular matrix (ECM)
remodeling, and embryonic development (Whitman and Raftery, 2005). Increasing evidence also
reveals the involvement of this pathway in the pathogenesis of cancer, fibrotic, cardiovascular,
and autoimmune diseases (Akhurst, 2004

Waite and Eng, 2003). In spite of the diverse

outcomes of this pathway, the central signaling cascade is rather simple and well established. In
response to TGFβ superfamily ligands, a hetero-tetrameric receptor complex is formed at the cell
surface comprising the type I receptor and the type II receptor (Liu et al., 1995

Wrana et al.,

1992). Type II receptors directly activate type I receptors by phosphorylating key serine residues
in the latter’s GS domain. Receptor-regulated Smads (R-Smads) are then phosphorylated in their
C-terminal SXS motif by the active type I receptor (Kretzschmar et al., 1997

Macias-Silva et

al., 1996). Phosphorylation of R-Smads promotes the heterotrimeric complex formation with CoSmads and their accumulation in the nucleus to regulate downstream gene expression (Inman
and Hill, 2002; Kretzschmar et al., 1997; Lagna et al., 1996

Wu et al., 1997; Zhang et al.,

1996). It is thought that the multiple diverse outcomes of this signaling pathway might in part
rely on the participation of transcriptional cofactors, such as SHN, a large zinc finger
transcription cofactor (Dai et al., 2000; Feng and Derynck, 2005

Marty et al., 2000). Recent

studies also demonstrate the cell-specific master transcription factors determine the genes that
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Smad1/2/3 bind to and thus regulate the cell-specific responses of TGFβ signaling (Mullen et al.,
2011; Trompouki et al., 2011). However, the existence of transcriptional cofactors cannot fully
explain the diverse, context-dependent activities of TGFβ pathway.
The Smad proteins consist of two conserved globular domains (MH1 and MH2 domains)
connected by a linker region (Shi and Massagué, 2003). The phosphorylation of the two Cterminal serine residues by type I receptor is essential to maintain the activity of TGFβ pathway.
In contrast, MAPK phosphorylation of the linker region somehow inhibits Smad1 activity
(Aubin et al., 2004; Kretzschmar et al., 1997; Pera et al., 2003). It is further demonstrated that
linker phosphorylation restricts Smad1 activity by enabling Smad1 recognition by the HECTdomain ubiquitin ligase Smurf1 (Sapkota et al., 2007). Sapkota and coworkers also showed
evidence that the inhibitory Smad1 linker phosphorylation can be induced not only by mitogens
and cellular stresses, but also by the BMP pathway itself (Sapkota et al., 2006). Similar findings
were made with Smad2 as a target of mitogens and Ras oncogene activation (Grimm and
Gurdon, 2002; Kretzschmar et al., 1999). Taken together, the linker phosphorylation of Smad
proteins provides feed-back control to TGFβ signaling, therefore modulating this pathway to
fulfill its diverse physiological roles.
Reversible phosphorylation, executed by kinases and phosphatases, constitutes an
essential regulatory mechanism in all living organisms. Recent studies have identified a plethora
of protein serine/threonine phosphatases (PSPs) modulating TGFβ pathway. For instance, the
phosphatase PPM1A antagonizes TGFβ signaling by dephosphorylating the very C-terminus of
all R-Smads (Duan et al., 2006; Lin et al., 2006). The pyruvate dehydrogenase phosphatase (PDP)
and the small C-terminal domain phosphatases (SCPs) modulate BMP signaling by
dephosphorylating mammalian and Drosophila Smad 1/5 at the C-terminal SSXS motif (Chen et
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al., 2006; Knockaert et al., 2006). In vertebrates, different B subunits of PP2A demonstrate
distinct roles in the regulation of TGFβ/Activin/Nodal signalling: Bα enhances signaling by
stabilizing the basal levels of type I receptor, whereas Bδ negatively regulates these pathways by
restricting receptor activity (Batut et al., 2008). Whereas, the Bβ subunit regulates BMP
signaling by dephosphorylating both the C-terminus and linker region of Smad1, with the linker
region as the preferred site, therefore leading to an overall amplification of BMP signaling
(Bengtsson et al., 2008). The regulatory subunit of PP1, GADD34, interacts with the catalytic
subunit of PP1 to dephosphorylate TGFβI, with or without the assistance of inhibitory Smads,
Smad6 or Smad7, attenuating the TGFβ signaling cascade (Shi et al., 2004).
In the nematode Caenorhabditis elegans, the BMP-related factor DBL-1 regulates body
size and male tail morphogenesis via a conserved receptor/Smad signaling pathway, the
Sma/Mab pathway (Gumienny and Savage-Dunn, 2013). The genome of Caenorhabditis elegans
is fully sequenced and one can carry out large-scale RNAi screens in Caenorhabditis elegans
simply by feeding, Caenorhabditis elegans provides an easy-to-use system to identify novel
players within signal pathways in vivo. In our search for novel protein phosphatases modulating
the Sma/Mab pathway, we found a protein serine/threonine phosphatase PPM-1 (protein
phosphatase Mg2+/Mn2+-dependent-1). PPM-1 belongs to the metal-dependent protein
phosphatase (PPM) family. The PPM family includes protein phosphatases dependent on
magnesium/manganese ions, such as PP2C and PDP. Members of this family do not have
regulatory subunits but contain characteristic C-terminal or N-terminal (or both) extensions that
may help to determine substrate specificity (Shi, 2009). Here we present genetic and functional
evidence that PPM-1 acts as a positive regulator of the Sma/Mab pathway.
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III.3 Materials and Methods
Strains and Caenorhabditis elegans protein phosphatase RNAi clones
C. elegans strains were cultured and maintained using standard methods at 20

unless

otherwise noted (Brenner, 1974). The following strains were used: N2 Bristol (wild type), LG II:
rrf-3(pk1426), sma-6(e1482), sma-6(wk7); LG III: sma-2(e502), sma-3(wk30); LG V: dbl1(wk70), ppm-1/tag-93(ok578), ppm-1/tag-93(tm653) ; LG X: ctIs40 (DBL-1 over-expressing
strain), and lon-2(e678).
LW2286 (lon-2(e678)X; jjls2277), LW2308 (dbl-1(wk70)V; jjls2277), and LW2436
(jjls2277) (gifts from Jun Kelly Liu, Cornell University) were used in RAD-SMAD reporter
assay. JY2 (qcIs54(col-41p::2xNLS::mCherry; myo-2p::gfp)) (Yin et al., unpublished data) was
used in a secondary reporter assay.
Bacterial clones from the Caenorhabditis elegans phosphatase RNAi library were
purchased from Source BioScience Life Science. All bacterial clones were grown on LB agar
plates supplemented with carbenicillin (25 µg/ml) and tetracycline (12.5 µg/ml) right before use.
RNAi feeding
RNAi feeding was performed as described in Section II.2. Briefly, 10-12 L4 animals
were transferred to feeding plates, incubated overnight, transferred to fresh feeding plates to lay
eggs for 4 hours and the stage-synchronized progeny were scored. For the body size phenotype,
RNAi hypersensitive rrf-3 mutants were used and the resulting synchronized progeny were
scored at the young adult stage.
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Analysis of body size measurements:
The body length of the resulting progeny was measured using Image-Pro Express
5.1.0.12 software. Student t-test was done to analyze the significance of the data (p<0.01).
Epistatic study
To investigate the genetic interaction with the known core components in Sma/Mab
pathway, we carried out an epistatic study in the following mutant backgrounds: a strong loss-offunction type I receptor mutant (sma-6(wk7)), a weak loss-of-function type I receptor mutant
(sma-6(e1482)), a loss-of-function mutant in a negative regulator of this Sma/Mab pathway (lon2), a strain that over-expresses the TGFβ ligand, DBL-1, (dbl-1(ctIs40)), and two SMA protein
mutant backgrounds: sma-2(e502)III, and sma-3(wk30)III.
The mutant worms were fed on ppm-1/tag-93 RNAi clones as described in RNAi feeding
part. The resulting 72 hour-old progeny were photographed and the body length was analyzed.
Reporter assay
To determine whether ppm-1 regulates body size directly through the Sma/Mab pathway
or through interactions with other components in this signal cascade, reporter assays were carried
out using two reporter constructs: RAD-SMAD reporter (Tian et al., 2010) and col41p::2xNLS::mCherry (Yin et al., unpublished data). Briefly, 10-12 L4 animals were transferred
to feeding plates seeded with the appropriate protein phosphatase RNAi clones, incubated
overnight, and transferred to fresh feeding plates to lay eggs for 4 hours. The synchronized
progeny were then scored at L2 stage when the expression of RAD-SMAD reporter in
hypodermis becomes predominant. The col-41p::2xNLS::mCherry reporter activity was checked
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in L3 and early L4 stage when the strongest expression was observed in hyperdermal nuclei.
Molecular cloning and Sequencing
To study whether ppm-1 has conserved function among species, the Xenopus homolog of
ppm-1, ppm1b, was identified by blasting the PPM-1 protein sequence in Xenbase
(www.xenbase.org). A full-length cDNA clone of Xenopus tropicalis ppm1b was purchased
from Source Bioscience Lifesciences (Product ID:IRBNp992H1213D). The cDNA insert was
amplified using the following primer pair with SalI restriction site introduced in the 5’ end and
NotI restriction site added in the 3’ end. The underlined sequences indicate the corresponding
restriction sites.
Forward primer: 5’ CGGTCGACATGGGGGCATTTTTGGAC
Reverse primer: 5’ GTGCGGCCGCTACCAGGGGTCTTCTAG
The amplified PCR products were cloned into an expression vector, pCS2++. The
resulting recombinant plasmid was then confirmed by sequencing and subject to further
investigation by Dr. Daniel Weinstein’s lab in a collaborative project.
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III.4 Results
III.4.1 PPM homologs regulate Caenorhabditis elegans body size
In the nematode Caenorhabditis elegans, a conserved TGFβ signaling pathway, the
Sma/Mab pathway, regulates body size and male tail morphogenesis (Savage-Dunn, 2013). We
hypothesized that protein phosphatases modulating this pathway might contribute to a body size
phenotype upon RNAi. In our primary screen using the Caenorhabditis elegans protein
phosphatase RNAi library and rrf-3 RNAi-hypersensitive mutant, we identified 4 homologs of
human PPM1A including ppm-1 (formerly tag-93) that is discussed through this chapter.
ppm-1, ppm-2, fem-2, and the uncharacterized C42C1.2 encode members of the PPM
family. When knocked down by RNAi, all four RNAi clones lead to a Sma phenotype in the rrf3 hypersensitive background (Figure.3.1).

Figure.3.1 Distinct PPM family members play a role in C. elegans body size
regulation. *: tested by student t-test, p<0.01. Error bar: standard error. N (worms
scored per RNAi treatment per experiment) ≥30.
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Among these four genes, only ppm-1 regulated a Sma/Mab pathway transcriptional
reporter, the RAD-SMAD reporter (Table 3.2), so we focused our studies on the ppm-1 gene.

III.4.2 PPM-1 (formerly named as tag-93) acts as a potential positive regulator in body size
control
In our primary screen, we found that ppm-1, temporarily named tag-93, caused a
significant body length decrease. In three independent RNAi experiments, the body length of rrf3 worms upon ppm-1/tag-93 RNAi was decreased by 4.9-8%, respectively (p<0.01, Table 3.1).
The protein product of ppm-1/tag-93 is conserved with three human PP2C protein
phosphatases, PP2Cα/PPM1A, PP2Cβ/PPM1B, and PPM1G (F25D1.1a: 49% identity and 69%
similarity with PPM1A; 54% identity and 72% similarity with PPM1B; 40% identity and 61%
similarity with PPM1G) (Stern et al., 2007; wormbase blast result). Based on this protein
phosphatase

homology,

tag-93

was

renamed

as

ppm-1

(protein

phosphatase

magnesium2+/manganese2+-dependent-1) (Tulgren et al., 2011).
Three open reading frames of ppm-1 are predicted in the Caenorhabditis elegans genome:
F25D1.1a, F25D1.1b, and F25D1.1c (www.wormbase.org).

F25D1.1a encodes a protein

sequence of 464-amino-acid which has an N-terminal extension besides the predicted catalytic
domain and the C-terminal regulatory domain. Whereas F25D1.1b and F25D1.1c encode a
protein sequence of 367-amino-acid and a protein sequence of 385-amino-acid, respectively.
Both F25D1.1b and F25D1.1c lack the N-terminal extension. All predicted ORFs have the two
conserved aspartic acid (D) residues which are essential to maintain the protein phosphatase
activity. Mutagenesis studies on human PP2Cα showed that mutations of residue D60 and D239
led to 900- and 4000-fold decreases in phosphatase activity, respectively (Jackson et al., 2003).
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PPM-1 (protein phosphatase Magnesium2+/Manganese2+-dependent-1) is a protein
serine/threonine phosphatase, belonging to the PPM family. Members of this family do not have
regulatory subunits but contain instead additional domains and conserved motifs that may confer
substrate specificity. PPM-1 is conserved in diverse species. As seen in Figure 3.1,
Caenorhabditis elegans PPM-1 proteins have the highest homology with human PPM1G.
Compared with human PPM1B, Caenorhabditis elegans PPM1 is more closely related with the
human PPM1A.
We then tested the body size phenotype with two genetic mutant alleles of ppm-1: ok578
and tm653. ok578 has a 984 bp deletion and two thymidine insertion, which causes a frameshift
resulting in a loss of sequence after amino acid 69. Importantly, it also causes the deletion of a
key catalytic residue D246 (corresponding to human PP2Cα D239). The deletion allele tm653
has a 1089 bp deletion which spans a portion of the promoter region, the start codon, and the first
156 amino acids including a catalytic residue D62 (corresponding to human PP2Cα D60).
Therefore, both ok578 and tm653 are believed to be molecular null mutants. Surprisingly, we
found that both alleles did not show any body size change at the young adult stage when
compared with wild type (N2 Bristol) worms (data not shown). However, the two deletion alleles
we used in our initial body size examination are not outcrossed, therefore we cannot rule out the
possibility that other undesirable mutations in the strains masked the effects of the ppm-1
mutations, leading to an undetectable body size change.
Table 3.1 ppm-1 positively regulates body length in rrf-3 RNAi-hypersensitive
mutant background
Trial
1

Control RNAi,
µm

ppm-1 RNAi,
µm

1364.87±49.13 1282.38±77.68

Percentage change%
(normalized to control
worm body length)
-6.04

P from student
t-test
6.78E-05
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2
3

1238.45±38.26 1177.69±48.01
1253.54±51.87 1153.04±44.39

-4.91
-8.02

6.12E-07
2.39E-13

1

Body length is measured in µm ± standard deviation at 72 hours after egg collection.
Control RNAi: rrf-3 worms are fed on HT115 bacteria containing only L4440 RNAi
feeding vector.
3
At least 30 worms are measured per sample.
2

Figure 3.2 ppm-1 is conserved among different species. The phylogenetic tree is
built using Clustal Omega software from EBI website. Protein sequences are obtained
from NCBI database. The protein IDs used are listed as below. C. elegans PPM-1
isoforms: WP:CE05722, WP:CE36134, WP:CE41642; C. elegans PPM homologs:
WP:CE02878, WP:CE24009, WP:CE42705; Homo sapiens PPM1A isoforms:
NP_066283.1, NP_808820.1, NP_808821.2; Homo sapiens PPM1B isoforms:
NP_002697.1, NP_808907.1, NP_808908.1, NP_001028728.1, NP_028729.1,
AAY89642.1, O15355.1; Xenopus laevis PPM1B isoforms: NP_001085342.1,
NP_001085063.1.
III.4.3 ppm-1 genetically interacts with Sma/Mab pathway components
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The Sma/Mab pathway plays a major role in body size regulation in C. elegans.
Mutations in any components of the pathway, dbl-1 (ligand), sma-6 (type I receptor), daf-4 (type
II receptor), sma-2, sma-3, sma-4 (Smad transcription factors), sma-9 (transcription co-factor)
result in smaller bodies than wild type (Estevez et al. 1993; Krishna et al. 1999; Liang et al.
2003; Savage-Dunn 2013; Savage-Dunn et al. 2003; Savage et al. 1996; Suzuki et al. 1999).
In our primary screen for novel players in Sma/Mab pathway, we found that depletion of
ppm-1 by RNAi, the rrf-3 worms exhibited a Sma phenotype as seen in core Sma/Mab
component mutants. I next determined whether the ppm-1 regulates body size in parallel to the
Sma/Mab pathway, or if it directly acts on the Sma/Mab components using epistatic analysis.
Epistasis analysis was performed using different genetic backgrounds that were wild-type for rrf3, so we first established whether ppm-1(RNAi) has an effect on N2. In our assay conditions,
ppm-1(RNAi) did not reduce the average length of N2 (Figure 3.3), so negative results obtained
in other genetic backgrounds must be considered inconclusive.
I performed epistasis analysis with the dbl-1 overexpression phenotype using dbl-1(ctIs40)
transgenic worms. Overexpression of dbl-1 results in a long (Lon) body phenotype. The Lon
phenotype of dbl-1 overexpression is suppressed in sma-2, sma-3, sma-4, sma-6 or daf-4 mutant
backgrounds, placing the activity of these small (Sma) genes downstream of the DBL-1 ligand
activity (Suzuki et al. 1999). If the ppm-1 gene activity were downstream of DBL-1, while
depleted by RNAi, we would expect a suppression of the Lon phenotype as observed with the
known small (Sma) genes in this pathway. I fed dbl-1 overexpressing worms on ppm-1 RNAi
plates. However, rather than the expected suppression of the Lon phenotype, the body length did
not change significantly (Figure.3.3).
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I next examined the RNAi effect on the lon-2(e678) mutant background. LON-2 is a
conserved member of the glypican family of heparan sulfate proteoglycans, a family with several
members known to regulate growth-factor signaling in many organisms. Epistasis tests with
Sma/Mab pathway component mutants: dbl-1(wk70) and sma-6(wk7) placed lon-2 as a negative
upstream regulator of this pathway (Gumienny et al., 2007). lon-2 mutations produce the dbl-1
overexpression body size phenotype. Animals are 14-26% longer than wild type worms. Upon
ppm-1 RNAi, lon-2 worms show significant body length decease (3.14% decrease compared
with worms fed on control RNAi, Figure 3.3, p<0.01). The suppression of lon-2 Lon body size
phenotype placed ppm-1 downstream of lon-2. Since LON-2 acts at the level of ligand-receptor
interactions, PPM-1 might act downstream of the ligand-receptor level.
I next examined the effect of ppm-1 on sma-6(wk7), a strong loss-of-function allele of
sma-6, by feeding the mutant worms with ppm-1 ds-RNA expressing bacteria, and observed no
significant body size change in the resulting progeny (Figure 3.3). This suggests that ppm-1
might be involved directly in the Sma/Mab pathway. Otherwise, we should have observed an
additive body size phenotype upon ppm-1 RNAi. The same result was found when tested with
sma-6(e1482), a weak loss-of-function allele of sma-6 (Figure 3.3). However, it is a little bit
surprising that we did not find any enhanced Sma phenotype under the sma-6(e1482)
background upon ppm-1 RNAi, since this allele only partially reduces Sma/Mab signaling.
Recent studies pointed out that human PPM1A/PP2Cα terminates TGFβ signaling
through dephosphorylation of Smad2/3 and facilitate the nuclear export of dephosphorylated
Smad2/3 (Lin et al., 2006). As ppm-1 is conserved with human PPM1A/PP2Cα (49% identity
and 69% similarity), we were curious about the genetic interaction between ppm-1 and SMA
proteins in Caenorhabditis elegans. Double knock-down experiments were carried out by
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investigating sma-2 and sma-3 mutants upon ppm-1 RNAi. The body size phenotype of the
resulting progeny was scored. Surprisingly, RNAi against ppm-1 only led to the enhanced Sma
phenotype in sma-2(e502) mutants (p<0.01, Figure 3.3). In contrast, the body size of sma3(wk30) animals did not exhibit any significant change upon ppm-1 RNAi (Figure 3.3).
Taken together, these epistasis tests suggest that ppm-1 genetically interacts with core
Sma/Mab pathway components. One possible regulatory mechanism requires the presence of
intact SMA-3.

Figure 3.3 ppm-1 genetically interacts with Sma/Mab pathway components. Epistasis
studies revealed that ppm-1 regulates C. elegans body size via the Sma/Mab pathway. *
indicates that the mutant alleles tested showed a significant decrease in body length upon
ppm-1 RNAi (analyzed by student t-test, p<0.01). Control worms were fed on HT115
bacteria containing only L4440 feeding vector. Error bar: standard error. N (worms
scored per RNAi treatment per experiment) ≥30.
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III.4.4 ppm-1 acts through Sma/Mab pathway to regulate Caenorhabditis elegans body size
Our previous epistatic studies have shown that ppm-1 genetically interacts with Sma/Mab
pathway components. The results suggest that ppm-1 might act as a positive regulator
downstream of DBL-1 ligand and its receptors to modulate the Sma/Mab pathway activity. We
also figured out that the downregulation of ppm-1 leads to an enhanced Sma phenotype in a sma2 mutant background but not in sma-3 mutants, suggesting the involvement of SMA-3 protein in
the normal function of PPM-1.
To further validate our conclusion that ppm-1 modulates Caenorhabditis elegans body
size through the Sma/Mab signal cascade, we carried out reporter assays using two reporter
constructs: RAD-SMAD reporter (gift from Jun Kelly Liu, Cornell University) and col-41
promoter-driving fluorescent reporter (col-41p::2xNLS::mCherry; myo-2p::gfp) (Yin et al.,
unpublished data). The RAD-SMAD reporter is an efficient research tool used to identify novel
players in the Sma/Mab pathway because of its special design as discussed in Tian’s original
research paper (Tian et al., 2010). col-41 is confirmed as a target of Sma/Mab pathway in
previous studies (Liang et al., 2003; Savage-Dunn C, 2011).
We hypothesized that if ppm-1 really plays as a positive regulator of the Sma/Mab
pathway, downregulation of ppm-1 would result in a decrease of both RAD-SMAD and col-41
promoter-fused reporter activity. We then carried out the reporter assays. Upon ppm-1 RNAi,
worms integrated with RAD-SMAD reporter or col-41 promoter-drived reporter demonstrated a
significant decrease in reporter activity (Figure 3.4). This is consistent with our previous
epistasis study.
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Figure 3.4 ppm-1 positively regulates RAD-SMAD and col-41 promoter-driving
reporter activity. Upper panels: RAD-SMAD reporter expression upon RNAi.
Worm strain used: LW2436 (jjls2277). Upper left panel: Upon control RNAi,
hypodermic nuclear expression of gfp is clearly visualized. Upper right panel: ppm-1
down-regulation results in a significant decrease in hypodermal nuclear expression.
Lower panels: col-41 promoter-fused mCherry reporter activity is downregulated
upon ppm-1 RNAi. Lower left panel: Normal expression upon control RNAi.show
exactly the same pattern as RAD-SMAD reporter. Lower right panel: Weaker
hypodermic nuclear expression when worms were fed on ppm-1 RNAi clones.

III.4.5 Establishment of expression contructs used in Xenopus embryo assay
As we have shown in the phylogenetic tree (Figure 3.2), ppm-1 is a conserved PPM
family member among species. We wondered whether Xenopus PPM-1 homologs function in a
similar way as we have discovered in Caenorhabditis elegans. To address this question, I
constructed a recombinant plasmid using pCS2++ expression vector as a backbone. A full-length
Xenopus PPM1B cDNA insert was subcloned into pCS++vector as described in the Materials
and Methods part (III.3). This cDNA was selected because when blasting the C. elegans PPM-1
protein sequence in Xenbase, the best hit was Xenopus PPM1B. The resulting plasmid named as
pSX01 was then verified via sequencing and being further investigated in a collaborative project
with Dr. Daniel Weinstein’s lab.
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III.5 Discussion
III.5. 1 ppm-1 might act as a SMA-3 linker phosphatase, therefore positively regulating the
body sie in Caenorhabditis elegans
We have shown several lines of genetic and molecular biological evidence, revealing that
the C. elegans ppm-1 regulates worm body size in a manner dependent on the Sma/Mab pathway
activity. Epitatic analyses with the core Sma/Mab pathway components indicate that ppm-1 is
directly involved in this signaling cascade downstream of LON-2 activity.
Whereas studies in a sma-2 mutant and a sma-3 mutant suggested that the intact SMA-3
protein is essential for ppm-1 to carry out its normal physiological function. Though at this
moment, we have no direct evidence to show how this PPM-1 acts on SMA-3 to fulfill its
regulatory role, an analysis on the linker regions of SMAs (compared with known human Smads,
Sapkota et al., 2006) revealed that different from SMA-2, SMA-3 has some putative prolinedirected serine residues (Figure 3.5). This suggests that PPM-1 might serve as a Smad linker
phosphatase to regulate the Sma/Mab pathway activity. Further studies are needed to elucidate
the mechanism by which PPM-1 regulates the Sma/Mab pathway. More biochemical assays
could be done to determine the direct substrate of PPM-1 when worm-specific anti-SMA and /or
anti-phospho-SMA antibodies are available.
The two available deletion alleles of ppm-1 (believed as molecular null mutants based on
the sequence analysis compared with human PPM1A), ok578 and tm653, did not show a body
size phenotype when fed on regular bacterial strain, DA387. There are three possible
explanations for this finding. First, these alleles do not delete the entire coding sequence, so
possibly the N-terminal and C-terminal sequences of ppm-1 might confer some compensation
role and maintain the basal Sma/Mab signaling, therefore it is possible that the deletion mutants
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are not functional null mutants. Second, members of the PPM family have relatively conserved
catalytic domains. The RNAi clones we used on our research might also knock down other PPM
family members, leading to a more severe phenotype in RNAi experiments than mutant
phenotype. A third possible reason is as mentioned in the result part, since the commercially
available strains we used in our initial study are not outcrossed, we cannot rule out the possibility
that other undesirable mutations in the background masked the body size phenotype caused by
ppm-1 deletion.

Figure 3.5 Potential linker phosphorylation sites in SMA-3 but not SMA-2.
: Proline-directed serines, the conserved SP phosphorylation sites, are indicated.

The phylogenetic tree (Figure 3.2) indicates that though Caenorhabditis elegans PPM-1
is closely related with human PPM1A and PPM1B, it is evolutionarily more related to human
PPM1G. Human PPM1G, a nuclear protein serine/threonine phosphatase, is shown to be a
regulator of chromatin remodeling, mRNA splicing, and DNA damage (Beli et al., 2012; Kimura
et al., 2006). Recent studies suggest that PPM1G is implicated in cellular survival and neural
development (Foster et al., 2013). Our results suggest that it may also play a role in regulation of
TGFβ signaling activity.
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III.5. 2 The Caenorhabditis elegans homologs of human PPM1A/B/G regulate body size
through different mechanisms
In the epistatic studies and reporter assays, the four C. elegans PPM homologs exhibit
different phenotypes. As summarized in Table 3.2, fem-2 and ppm-2 enhanced the Lon
phenotype of both dbl-1 over-expressing allele and lon-2(e678) mutant whereas C42C1.2 and
ppm-1 suppressed the Lon phenotype of lon-2(e678) mutant, while exerting no effect on the dbl1 over-expressing allele phenotype (Lon by itself). In the RAD-SMAD reporter assay, only ppm1 shows a consistent phenotype with the epistatic research. Downregulation of ppm-1 results in a
weaker activity of RAD-SMAD reporter.
Further functional analyses are required to elucidate the roles of the distinct PPM family
members in Caenorhabditis elegans body size regulation and growth control.

Table.3.2 Distinct PPM family members regulate body size via different
mechanisms
Wormbase

rrf-3

sma-6(wk7)

dbl-1(ctIs40)

lon-2(e678)

annotation
fem-2

ppm-2

C42C1.2

RAD_-SMAD
reporter assay

Sma

Sma

Sma

NS

NS

NS

Enhanced

Enhanced

Lon

Lon

Enhanced

Enhanced

Lon

Lon

NS

Suppressed

NS

NS

NS

Lon
ppm-1

Sma

NS

NS

Suppressed

Weaker

74

Lon

Sma: Small phenotype; NS: no significant change; Lon: Long phenotype, tested by
student t-test, p<0.01
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Chapter IV. Distinct subunits of Protein Phosphatase-1 (PP1) negatively
regulate Caenorhabditis elegans body size partially through the Sma/Mab
pathway

IV.1 Abstract
Background: The transforming growth factor β (TGFβ) signaling cascade is an essential
signaling pathway both involved in various normal developmental events and the pathogenesis of
many diseases. Reversible phosphorylation is recently revealed as a crucial regulatory
mechanism to modulate this rather simple signal cascade to fulfill its diverse physiological roles.
In Caenorhabditis elegans, a conserved TGFβ pathway, the Sma/Mab pathway, controls body
size and male tail patterning. In our previous large-scale RNA screen searching for novel protein
phosphatase players regulating Sma/Mab pathway, protein phosphatase-1 (PP1) was identified.
We then studied the multiple PP1 subunits present in the Caenorhabditis elegans protein
phosphatase RNAi library using genetic and molecular biological techniques.
Results: We demonstrate here several lines of evidence indicating that the two Caenorhabditis
elegans homologues of human PPP1CB (phosphoprotein phosphatase-1, catalytic subunit, β
isoform), C06A1.3 and F58G1.3, and one homologue of human PPP1R2 (phosphoprotein
phosphatase-1, regulatory subunit, isoform 2), Y32H12A.4, act as negative regulators of the
Sma/Mab pathwayin body size control. Epistatic analyses suggest that SMA-6 acts downstream
of the PP1 subunit homologs.
Conclusion: The PP1 protein subunits negatively regulate Caenorhabditis elegans body size in a
manner dependent on the Sma/Mab pathway activity.
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IV.2 Introduction
Protein phosphatase activity plays an essential role to determine the extent and duration
of the cellular protein phosphorylation, in response to physiological stimuli. As reversible
phosphorylation executed by the interplay between protein kinases and protein phosphatases has
been firmly established as an essential, fundamental regulatory mechanism in all eukaryotes in
the past 50 years; and in the human genome, more than 420 genes encode serine/threonine
kinases, which account for 98.2% of all phosphorylation events (Peti et al., 2012); protein
serine/threonine phosphatases (PSPs) become extensively studied.
Protein serine/threonine phosphatases have at least three subfamilies, with the largest
family being the phosphoprotein phosphatases (PPP). The PPP family members, such as protein
phosphatase-1 (PP1) and protein phosphatase-2A (PP2A/PP2), have a structurally related
catalytic subunit and identical reaction mechanism but a distinct set of substrates and interacting
proteins. In contrast, all PPM family members, for example, protein phosphatase
magnesium2+/manganese2+-dependent-1A (PPM1A), are single polypeptides, which execute their
diverse roles, depending on splice variants and various isoforms. The FCP/SCP family is
characterized by a conserved DXDX(T/V) motif that is essential for their activity and that they
share with a superfamily of phosphotransferases and phosphohydralases (Chambers et al., 1994;
Kamenski et al., 2004). Among them, PP1 is the most extensively studied, as it is responsible for
about 30% of all dephosphorylation reactions in eukaryotic cells (Choy et al., 2012).
The metalloenzyme PP1 (~38.5 kDa, 2 Mn2+ are bound in the acive site when expressed
in bacteria) is exceptionally conserved in eukaryotes from fungi to human (Choy et al., 2012).
The mammalian genome contains three different genes that encode four distinct catalytic PP1
subunits: PP1α, PP1β/δ and the splice variants PP1γ1 and PP1γ2. The primary sequence
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differences among PP1 catalytic units are localized to the N- and C-termini. Free PP1 catalytic
subunits have essentially no substrate specificity. ≥200 PP1-interacting proteins (PIPs) are
identified in vertebrates (Heroes et al., 2013). These proteins target distinct PP1 holoenzymes to
particular cellular compartments, confer substrate specificity, and sometimes themselves serve as
substrates of PP1. PIPs include PP1 regulatory subunits and inhibitor proteins. ≥70% of these
regulatory proteins of PP1 belong to the class of IDPs (intrinsically disordered proteins)
including I-2 (inhibitor 2, which will be discussed in this study) (Choy et al., 2012).
The transforming growth factor β (TGFβ) signaling cascade controls a broad range of
cellular responses in metazoans, such as cell growth, differentiation, extracellular matrix (ECM)
remodeling and embryonic development (Whitman and Raftery, 2005). This signaling pathway
is also involved in the pathogenesis of human diseases, for instance, cancer, fibrotic,
cardiovascular, and autoimmune diseases (Akhurst, 2004

Waite and Eng, 2003). The canonical

signaling is mediated via TGFβ-induced phosphorylation receptor-activated Smads at the Cterminal SXS motif. The TGFβ ligand superfamily comprises two families of secreted peptide
growth factors: the TGFβ/Activin/Nodal/growth and differentiation factors (GDF) subfamily,
and the bone morphogenetic proteins (BMPs) subfamily (Massague and Chen, 2000

Roberts

and Sporn, 1993). Upon TGFβ ligand binding, a hetero-tetrameric receptor complex is formed at
the cell surface comprising the type I receptor and the type II receptor (Liu et al., 1995

Wang et

al., 1992). Type II receptors directly activate type I receptors by phosphorylating key serine
residues in the latter’s GS domain. Receptor-regulated Smads (R-Smads) are then
phosphorylated in their C-terminal SXS motif by the active type I receptor (Kretzschmar et al.,
1997

Macias-Silva et al., 1996). Phosphorylation of R-Smads promotes heterotrimeric complex

formation with Co-Smads and accumulation in the nucleus to regulate downstream gene
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expression (Inman and Hill, 2002; Kretzschmar et al., 1997; Lagna et al., 1996

Wu et al., 1997;

Zhang et al., 1996). It is thought that the multiple diverse outcomes of this signaling pathway
might in part rely on the participation of extra transcriptional cofactors, such as SHN, a large
zinc finger transcription cofactor (Dai et al., 2000; Feng and Derynck, 2005

Marty et al., 2000).

Recent studies suggest that cell-specific master transcription factors also contribute to the cellspecific responses of TGFβ signaling (Mullen et al., 2011; Trompouki et al., 2011). However,
the existence of transcriptional cofactors cannot fully explain the diverse, context-dependent
activities of TGFβ pathway.
The well-established kinase-mediated regulatory mechanisms of the TGFβ signaling
imply that reversible phosphorylation might play a crucial role in the modulation of the TGFβ
pathway activity. Recent studies have identified a plethora of protein serine/threonine
phosphatases (PSPs) that modulate the TGFβ pathway, such as protein phosphatase
magnesium2+/manganese2+-dependent-1A (PPM1A), the pyruvate dehydrogenase phosphatase
(PDP), and the small C-terminal domain phosphatase (SCP) (Chen et al., 2006; Duan et al., 2006;
Knockaert et al., 2006; Lin et al., 2006). Some members of the major family of protein
serine/threonine phosphatases, PPP family, are also found to play a role in the regulation the
TGFβ pathway, such as Bα, Bβ, and Bδ subunits of PP2A (Batut et al., 2008; Bengtsson et al.,
2008 ). Increasing evidence shows the involvement of various regulatory subunits of another
major PPP family member, PP1, in the regulation of TGFβ pathway (Shi et al., 2004; Han et al.,
2012). The regulatory subunit, GADD34, interacts with the catalytic subunit of PP1 to
dephosphorylate TGFβI with or without the assistance of inhibitory Smads, Smad6 or Smad7,
attenuating the TGFβ signaling cascade (Shi et al., 2004). Inhibitor 5 of protein phosphatase 1
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(IPP5) enhances transforming growth factor-β (TGF-β)/Smad signaling in a PP1-dependent
manner (Han et al., 2012).
In the nematode Caenorhabditis elegans, the BMP-related factor DBL-1 regulates body
size and male tail morphogenesis via a conserved receptor/Smad signaling pathway, the
Sma/Mab pathway (Savage-Dunn, 2013). In our previous large-scale RNAi screen to search for
novel protein phosphatases modulating Sma/Mab pathway, we found two orthologs of human
PP1 catalytic unit, β isoform (PPP1CB) and one ortholog of various PP1 regulatory (inhibitory)
subunit 2 proteins (PPP1R2). Here we present genetic and functional evidence that the orthologs
of human PP1 catalytic subunit and that of human PPP1R2 protein negatively regulate
Caenorhabditis elegans body size partially through the Sma/Mab pathway.
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IV.3 Materials and Methods
Strains and Caenorhabditis elegans protein phosphatase RNAi clones
C. elegans strains were cultured and maintained using standard methods at 20

unless

otherwise noted (Brenner, 1974). The following strains were used: N2 Bristol (wild type), LG II:
rrf-3(pk1426), sma-6(e1482), sma-6(wk7); LG III: sma-2(e502), sma-3(wk30); LG V: dbl1(wk70); LG X: ctIs40 (DBL-1 over-expressing strain), lon-2(e678).
LW2286 (lon-2(e678)X; jjls2277), LW2308 (dbl-1(wk70)V; jjls2277), and LW2436
(jjls2277) (gifts from Jun Kelly Liu, Cornell University) were used in RAD-SMAD reporter
assay. JY2 (qcIs54(col-41p::2xNLS::mCherry; myo-2p::gfp)) (Yin et al., unpublished data) was
used in a secondary reporter assay.
Bacterial clones from the Caenorhabditis elegans phosphatase RNAi library were
purchased from Source BioScience Life Science. All bacterial clones were grown on LB agar
plates supplemented with carbenicillin (25 µg/ml) and tetracycline (12.5 µg/ml) right before use.
RNAi feeding
RNAi feeding was performed as described in Section II.2. Briefly, 10-12 L4 animals
were transferred to feeding plates, incubated overnight, transferred to fresh feeding plates to lay
eggs for 4 hours and the stage-synchronized progeny were scored. For the body size phenotype,
RNAi hypersensitive rrf-3 mutants were used and the resulting synchronized progeny were
scored at the young adult stage.
Analysis of body size measurements:
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The body length of the resulting progeny was measured using Image-Pro Express
5.1.0.12 software. Student t-test was done to analyze the significance of the data (p<0.01).
Epistatic study
To investigate the genetic interaction with the known core components in Sma/Mab
pathway, we carried out epistatic study in the following mutant backgrounds: a strong loss-offunction type I receptor mutant (sma-6(wk7)), a weak loss-of-function type I receptor mutant
(sma-6(e1482)), a loss-of-function mutant in a negative regulator of this Sma/Mab pathway (lon2), in a strain that over-expresses the TGFβ ligand, DBL-1, (dbl-1(ctIs40)), and in two SMA
protein mutant backgrounds: sma-2(e502)III, and sma-3(wk30)III.
The mutant worms were fed on corresponding pp1 RNAi clones as described in RNAi
feeding part. The resulting 72 hour-old progeny were photographed and the body length was
analyzed
Reporter assay
To determine whether the subunits of pp1 regulates body size directly through Sma/Mab
pathway or through interaction with components in this signal cascade, reporter assays were
carried out using two reporter constructs: RAD-SMAD reporter (Tian et al., 2010) and col41p::2xNLS::mCherry (Yin et al., unpublished data). Briefly, 10-12 L4 animals were transferred
to feeding plates seeded with appropriate protein phosphatase RNAi clones, incubated overnight,
and transferred to fresh feeding plates to lay eggs for 4 hours. The synchronized progeny were
then scored at L2 stage when the expression of RAD-SMAD reporter in hypodermis becomes
predominant. The col-41p::2xNLS::mCherry reporter activity was checked in L3 and early L4
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stage when the strongest expression was observed in hyperdermal nuclei.
Molecular cloning and Sequencing
To study whether the subunits of pp1 have conserved functions among different species,
the Xenopus homologs were identified by blasting the corresponding Caenorhabditis elegans
protein sequence in Xenbase (www.xenbase.org). The full-length cDNA clones of Xenopus
homologs were purchased from Source Bioscience Lifesciences (Product ID: IRBHp990A1229D,
IRBHp990F022D, IRBHp990B0789D). The cDNA inserts were cut with SalI and NotI
restriction enzymes, gel-purified and re-ligated into the expression vector, pCS2++. The
resulting recombinant plasmids were then confirmed by sequencing and subject to further
investigation by Dr. Daniel Weinstein’s lab in a collaborative project.
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IV.4 Results
IV.4.1 Subunits of PP1 act as potential negative regulators in body size control
In the nematode Caenorhabditis elegans, a conserved TGFβ signaling pathway, the
Sma/Mab pathway, regulates body size and male tail morphogenesis (Savage-Dunn, 2013). We
hypothesized that protein phosphatases modulating this pathway might contribute to a body size
phenotype upon RNAi. In our primary screen using rrf-3 RNAi-hypersensitive mutant, we found
that three genes, C06A1.3, F58G1.3, and Y32H12A.4, caused a significant body length increase
upon RNAi (Figure 4.1). Knocking down C06A1.3, F58G1.3, and Y32H12A.4 led to a body size
increase in rrf-3 hypersensitive mutant worms by 14.2%, 11.1%, and 5.3%, respectively.
Among the three, C06A1.3 and F58G1.3 encode orthologs of human PP1 catalytic
subunit, β isoform (47% identity and 65% similarity with human PPP1CB; 46% identity and
65% similarity with human PPP1CB; respectively) (Figure 4.2). The protein product of
Y32H12A.4 is conserved with human PP1 regulatory (inhibitory) subunit 2 protein (PPP1R2)
(41% identity and 59% similarity with human PPP1R2). As indicated in the phylogenetic tree in
Figure 4.2, the catalytic subunits of PP1 identified from our primary large-scale RNAi screen are
conserved among metazoans; which suggests that they may function in a conserved manner. The
multisequence alignment of C. elegans, Xenopus, and human IPP-2s suggest the conservation of
their physiological function (Figure.4.3).
PP1 (protein phosphatase 1) is a protein serine/threonine phosphatase, belonging to the
PPP family. Functional members of this family consist of a catalytic subunit and a regulatory
subunit. In contrast to various regulatory subunits, the catalytic subunit of PP1 is highly
conserved among all eukaryotes and has relatively fewer isoforms in vivo. At least 200 putative
PP1-binding Regulatory (R) subunits have been identified, with many more expected to be found
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(Choy et al., 2012; Cohen, 2004; Moorhead et al., 2007). Analyses of known R subunits in
diverse eukaryotic lineages suggest that these R subunits may target the PP1 catalytic subunit to
specific cellular compartments, modulate substrate specificity, or serve as substrates themselves
(Shi, 2009). Since Y32H12A.4 (RNAi) causes the same mutant phenotype as knocking down
C06A1.3 and F58G1.3, our results suggest that this regulatory subunit positively regulates the
activity of the catalytic subunits.

Figure 4.1 The homologs of human PPP1CB and PPP1R2 negatively regulate C.
elegans body size. C06A1.3 and F58G1.3 are homologs of human PPP1CB, Y32H12A.4
is the homolog of human PPP1R2. *: Data are analyzed by student t-test, p<0.01. Error
bar: standard error. N (worms scored per RNAi treatment per experiment) ≥30.
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Figure 4.2 Distinct subunits of PP1 are conserved among different species. The
phylogenetic tree is built using Clustal Omega on-line free software at EMBL-EBI
website. Xenopus and human protein sequences are obtained from NCBI database.
C.elegans protein sequences are found at wormbase.org. The protein IDs used are as
follows. C.elegans PPP1CB homologs: WP:CE02116, WP:CE35562; Homo sapiens
PPP1CA: NP_001008709.1; Homo sapiens PPP1CB: NP_002700.1; Homo sapiens
PPP1CC: NP_001231903.1; Xenopus PPP1CA: NP_001120482.1; Xenopus PPP1CB:
NP_001011467.1.
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Figure 4.3 Putative IPP-2s are conserved among C. elegans, Xenopus, and
human.
The multiple sequence alignment is generated using the on-line clustal Omega
software at EBI website.

IV.4.2 The catalytic subunits and regulatory subunit of PP1 directly regulate the output of
Sma/Mab pathway in SMA-responsive reporter assay
Our previous studies have shown that all three subunits of PP1 identified regulate C.
elegans body size negatively and are conserved among species. Thus, we wanted to know
whether the regulation is dependent on the Sma/Mab pathway activity or not. To address this
question, I carried out reporter assays using two reporter constructs: RAD-SMAD reporter (gift
from Jun Kelly Liu, Cornell University) and col-41 promoter-fused flurescent reporter (col41p::2xNLS::mCherry; myo-2p::gfp) (Yin et al., unpublished data). RAD-SMAD reporter is an
efficient research tool used to identify novel players in the Sma/Mab pathway because of its
special design as discussed in Tian’s original research paper (Tian et al., 2010). COL-41 is
confirmed as a target of Sma/Mab pathway in previous studies (Liang et al., 2003; Savage-Dunn
C, 2011).
We hypothesized that if the three subunits of PP1 really play as negative regulators of the
Sma/Mab pathway, downregulation of the subunit genes would result in increase of both RADSMAD and col-41 promoter-fused reporter activity. We then carried out the reporter assays.
Upon RNAi of the three subunit genes, worms integrated with RAD-SMAD reporter
demonstrated a significant increase in activity (Figure. 4.4, panel B, C, D). This is consistent
with these genes acting via the Sma/Mab pathway. However, when assayed with col-41
promoter-fused reporter activity, the downregulation of all three subunit genes did not exhibit a

87

detectable change in the col-41 promoter-fused mCherry expression (data not shown). This is
likely to be explained by the nature of the reporter constructs themselves. RAD-SMAD reporter
has five-tandem Smad-binding site repeat that increases the responsiveness to the signal. Another
possible explanation is that col-41 might be an indirect target of Sma/Mab pathway, which is not
very sensitive to fine tuning regulation of Sma/Mab pathway executed by subunits of PP1.
Finally, it is possible that other compensatory mechanisms result in the normal regulation of col41 but not the artificial RAD-SMAD reporter.

Figure 4.4 All three subunits of PP1 identified from primary large-scale RNAi
screen negatively regulates RAD-SMAD reporter activity. Upper left panel:
RAD-SMAD reporter expression upon control RNAi. Upper right panel: Upon the
C. elegans homolog of human PPP1CB, C06A1.3, RNAi, hypodermal nuclear
expression of gfp is increasing. Lower left panel: The downregulation of another C.
elegans homolog of human PPP1CB, F58G1.3, RNAi, a significant increase of
hypodermic nuclear expression of gfp is clearly increased. Lower right panel:
Knocking down the C. elegans homolog of human PPP1R2, Y32H12A.4,
hypodermal nuclear expression of gfp is also increasing.

IV.4.3 The catalytic subunits of PP1 and the homolog of human PPP1R2 genetically
interact with Sma/Mab pathway components
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The Sma/Mab pathway plays a major role in body size regulation in C. elegans.
Mutations in any components of the pathway, dbl-1 (ligand), sma-6 (type I receptor), daf-4 (type
II receptor), sma-2, sma-3, sma-4 (Smad transcription factors), sma-9 (transcription co-factor)
result in smaller bodies than wild type (Estevez et al. 1993; Krishna et al. 1999; Liang et al.
2003; Savage-Dunn 2013; Savage-Dunn et al. 2003; Savage et al. 1996; Suzuki et al. 1999).
In our primary screen for novel players in the Sma/Mab pathway, we found that depletion
of the homologs of human PPP1CB, C06A1.3 and F58G1.3, respectively, in the rrf-3 mutant
background, resulted in a Lon phenotype as opposed to the major Sma/Mab component mutants.
Our RAD-SMAD reporter assay results are consistent with this finding, suggesting that these
subunits of PP1 identified regulate body size through a Sma/Mab pathway-dependent manner. I
next determined whether those structural subunits regulate C.elegan body size in parallel to
Sma/Mab pathway or directly acts on the Sma/Mab components using epistatic analysis.
I first examined the effect of these subunits on sma-6(wk7), a strong loss-of-function
allele of sma-6, by feeding the mutant worms with the corresponding ds-RNA expressing
bacteria. I observed no significant body size change in the resulting progeny, even in
F58G1.3(RNAi), a knockdown that causes a Lon phenotype in N2 as well as in rrf-3 (Table 4.1).
When tested with sma-6(e1482), a weak loss-of-function allele of sma-6, upon F58G1.3 RNAi,
the Sma phenotype of sma-6(e1482) mutant was suppressed significantly, though not rescued to
the wild-type level (Table 4.1, data not shown). Taken together, the data we obtained suggest
SMA-6 is downstream of these PP1 subunits in the Sma/Mab pathway.
To further validate this result, I then looked at the dbl-1 overexpression phenotype using
dbl-1(ctIs40) transgenic worms. Overexpression of dbl-1 results in a long (Lon) body phenotype.
The Lon phenotype of dbl-1 overexpression is suppressed in sma-2, sma-3, sma-4, sma-6 or daf-

89

4 mutant backgrounds, placing the activity of these small (Sma) genes downstream of the DBL-1
ligand activity (Suzuki et al. 1999). I fed dbl-1 overexpressing worms on the corresponding PP1
subunit RNAi plates.

Both homologs of human PPP1CB protein, C06A1.3 and F58G1.3,

enhanced the Lon phenotype of dbl-1 overexpressing transgenic worms. In contrast, the
downregulation of Y32H12A.4 gene did not change the body size phenotype of this strain
(Table.4.1). Since we visualized an additive body size phenotype, these data indicate that the
regulation of Sma/Mab pathway by PP1 subunits might partially act through a Sma/Mabindependent manner.
I next examined the RNAi effect on lon-2(e678) mutant background. LON-2 is a
conserved member of the glypican family of heparan sulfate proteoglycans, a family with several
members known to regulate growth-factor signaling in many organisms. Epistasis tests with
Sma/Mab pathway component mutants: dbl-1(wk70) and sma-6(wk7) placed lon-2 as a negative
upstream regulator of this pathway (Gumienny et al., 2007). lon-2 mutations produce the dbl-1
overexpression body size phenotype. Animals are 14-26% longer than wild type worms. Upon
C06A1.3 RNAi, lon-2 worms show significant body length increase (3.05% increase compared
with worms fed on control RNAi, data not shown, p<0.01). In contrast, another homolog of
human PPP1CB, F58G1.3, did not exhibit any effect on the body size phenotype of lon-2
animals. However, the downregulation of Y32H12A.4, the homolog of human PPP1R2, leads to a
similar enhanced Lon phenotype in lon-2 worms. This suggests that these PP1 subunits might act
partially independent of LON-2 to modulate the Sma/Mab pathway. These findings are
consistent with the previous results we found in the epistatic analyses using sma-6 mutants and
ctIs40 dbl-1-overexpressing transgenic worms.
Table 4.1 All three subunits of PP1 identified from the primary RNAi screen
genetically interact with Sma/Mab pathway components
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Wormbase

N2

sma-6(wk7)

sma-6(e1482)

dbl-1(ctIs40)

lon-2(e678)

NS

NS

ND

Enhanced

Enhanced

Lon

Lon

Suppressed

Enhanced

NS

Sma

Lon

ND

NS

annotation
C06A1.3,
human
PPP1CC-like
F58G1.3,
human

Lon

NS

PPP1CC-like
Y32H12A.4,
human

NS

NS

Enhanced

PPP1R2-like

Lon

Lon: long body size phenotype; NS: no significant chance; ND: not determined.
All data are analyzed with student t-test, p<0.01.

IV.4.4 Establishment of expression constructs used in Xenopus embryo assay
As we have shown in the phylogenetic tree (Figure 4.2), the catalytic subunits and the
inhibitory regulatory subunit of PP1 are conserved among the selected species. Both C06A1.3
and F58G1.3 share a 47% sequence identity with Xenopus PPP1CB protein and have an overall
77% sequence similarity, which suggests their conserved physiological functions in vivo. The
Caenorhabditis elegans homolog of human PPP1R2, Y32H12A.4, also shows conservation in its
sequence compared with Xenopus counterpart (a 38% identity and an overall 65% similarity).
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In our previous studies, we have presented several lines of evidence to show that the three
subunits of PP1 modulate Caenorhabditis elegans body size in a Sma/Mab pathway-dependent
manner. However, due to the inavailability of phosphor-SMA-specific antibodies, we could not
show directly on worms whether these PP1 subunits use Sma/Mab components as direct
substrates to regulate its activity or through an indirect mechanism. And since we are also
curious about whether the protein phoshatase candidates from our screen have a conserved
function among species, we have started a collaborative project with Dr. Daniel Weinstein’s lab.
As mentioned in the Materials and Methods section, a series of recombinant plasmids were
constructed (Table 4.2). The resulting plasmids were sequencing verified and tested in Xenopus
embryo assay. Surprisingly, microinjection of double-strand RNAs of single PP1 subunit did not
exhibit any detectable phenotype. This might be partly explained by the conpensation of other
catalytic subunit isoforms, which maintains the normal activity of BMP signaling within
Xenopus embryo (data not shown). Coinjection with both catalytic and regulatory subunit dsRNA might lead to a more predominant phenotype and is worth trying.
Table.4.2 The recombinant plasmid constructs used in Xenopus embryo assay

Construct name

Caenorhabditis elegans

Xenopus cDNA insert

homolog
pCS393

C06A1.3

PPP1CB

pCS394

F58G1.3

PPP1CA

pCS395

Y32H12A.4

PPP1R2
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IV.5 Discussion
IV.5.1 Two homologs of human PPP1CB act as negative regulators of the Sma/Mab
pathway to modulate the body size in Caenorhabditis elegans
We have shown several lines of genetic and molecular biological evidence, revealing that
the two C. elegans homologs of human PPP1CB, C06A1.3 and F58G1.3, negatively regulate
worm body size in a manner dependent on the Sma/Mab pathway activity. Epitatic analyses with
the Sma/Mab pathway components placed the two proteins upstream of SMA-6 receptor.
The suppressed Sma phenotype exhibited by sma-6(e1482) mutants upon the F58G1.3
RNAi suggests that the protein products of this gene executes its growth control role through a
SMA-6-dependent manner. In the strong loss-of-function allele, sma-6(wk7), knocking down this
gene has no effect on the mutant Sma phenotype. Taken together, intact SMA-6 is required for
normal function of the Caenorhabditis elegans PPP1CB proteins identified in our study. This is
consistent with the findings that PP1 serves as a receptor phosphatase to regulate the TGFβ
signaling.

IV.5.2 The Caenorhabditis elegans homolog of human PPP1R2 is a negative modulator of
the Sma/Mab pathway
The catalytic subunit of PP1 is regulated by the heat-stable protein inhibitor-1, its
homologue DARPP-32 (dopamine-and CAMP-regulated phosphoprotein, Mr 32,000) and
inhibitor-2 (Watanabe et al., 2001). Wang and his colleague showed in their study that a novel
membrane protein KPI-2 (Kinase/Phosphatase/Inhibitor-2) associates with PP1C the protein
phosphatase inhibitor-2 form a regulatory complex localized at the membrane (Wang et al, 2002).
Neurabins recruit protein phosphatase-1 and Inhibitor-2 to the actin cytoskeleton and regulate
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cell morphology (Terry-Lorenzo et al., 2002). The increasing evidence shows the importance of
Inhibitor-2 (PPP1R2) in the regulation of PP1-mediated signaling.
In our study, the Caenorhabditis elegans homologue of human PPP1R2, Y32H12A.4, was
shown to regulate body size through a Sma/Mab pathway-dependent manner. The epistatic
analyses suggest that besides the regulation through the Sma/Mab pathway, Y32H12A.4 might
also modulate body size through signaling cascades independent of Sma/Mab pathway. Upon
RNAi, Y32H12A.4 enhanced the Lon phenotype of lon-2 mutants while had no effect on the dbl1 over-expressing phenotype and the Sma phenotype of sma-6(wk7) mutants. These data
suggested that in the Sma/Mab pathway, Y32H12A.4 may act upstream of the SMA-6 receptor to
regulate its activity.
Although we presented several lines of genetic and molecular biological evidence and
revealed the important role of the three subunits of PP1 in the regulation of Caenorhabditis
elegans body size as negative modulators, the molecular mechanism of this regulatory event
remains largely unkown. For instance, whether the three subunits cooperate to regulate the
Sma/Mab pathway or act independently is not addressed yet. The direct substrates or potential
interacting partners are not determined.
Our study has just opened a window to investigate the regulatory machinery of PP1
catalytic subunits on the Sma/Mab pathway, which in turn will further the understanding of the
TGFβ signaling regulation mechanism among mammalian systems, and provide more
therapeutic targets in human diseases.
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Chapter V. Perspective
V.1

Functional studies to characterize the roles of PPM-1 and PP1 subunits
in the regulation of Caenorhabditis elegans body size via the Sma/Mab
pathway
As indicated in our studies described in previous chapters, we carried out a large-scale

RNAi screen using Caenorhabditis elegans as a model system and identified a plethora of
protein modifiers regulating body size (summarized in Chapter 2, Table 2.2 and Table 2.3).
Some of these protein phosphatase candidates are involved in Sma/Mab pathway regulation to
modulate worm growth (Chapter 2, Table 2.7). Among them, the protein Ser/Thr phosphatase
(PS/TP) family was our first priority to characterize because the core event of TGFβ signaling is
the ligand-induced phosphorylation of R-Smad proteins at the C-terminal SXS/T motif. The
members of the PS/TP family were therefore studied. ppm-1 was shown in our study as a
positive modulator controlling body size via the Sma/Mab pathway; whereas three subunits of
PP1, C06A1.3, F58G1.3, and Y32H12A.4, emerged as negative regulators modulating body size
in a Sma/Mab-dependent pathway (discussed in Chapters 3 and 4, respectively).
However, our study is just the initiation of the research to elucidate the possible
mechanisms by which these protein Ser/Thr phosphatases regulate the Sma/Mab pathway
activity. First, the direct substrate(s) of the three PS/TPs are not identified yet. Second, the
temporal and spatial expression patterns of the candidates are not investigated and how they
interact with the Sma/Mab pathway components require further investigation. Third, whether
these PS/TPs work in a discrete manner or somehow through the crosstalk of different signaling
pathways to cooperate in the regulation of the Sma/Mab pathway remains unclear and worth of
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further research. Fourth, the exact position of these four PS/TPs in the Sma/Mab pathway need to
be further studied using the corresponding mutants crossed with known Sma/Mab component
mutants.
In summary, we identified protein phosphatases involved in the regulation of the
Sma/Mab pathway. Since TGFβ signaling is conserved in all metazoans, our findings will
contribute to the elucidation of the fine-tuned regulation of this signaling cascade, therefore
facilitating the discovery of possible therapeutic targets in TGFβ-related human diseases, such as
cardiovascular diseases, fibrotic diseases, and cancer.

V.2

Protein Tyrosine Phosphatase(s): an emerging role in the regulation of
the Sma/Mab pathway
The Sma/Mab pathway is activated by the ligand-induced phosphorylation of of R-Smad

proteins at the C-terminal SXS/T motif. In brief, upon DBL-1 ligand binding, the type II receptor
DAF-4 phosphorylates the type I receptor SMA-6 at the serine residues in the GS domain. Then
the phosphorylated type I receptor SMA-6 in turn phosphorylates R-Smads, SMA-2 and SMA-3.
The active SMA-2 and SMA-3 complexes with Co-Smad SMA-4 and translocates into the
nucleus to regulate Smad-responsive gene expression with or without transcriptional cofactors,
such as SMA-9.
Studies have revealed that the constitutively active type II receptor requires
autophosphorylation at Ser213 and Ser409 for full kinase activity and the ability to interact with
and activate the type I receptor (Luo et al., 1997). The type II receptor can also
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autophosphorylate on Tyr259, 336 and 424, which is thought to play a role in regulating type II
kinase activity (Lewler et al., 1997). The type II receptor was also demonstrated to undergo Srcmediated phosphorylation at Tyr284 (Galliher et al., 2006; Galliher et al., 2007). In addition to
the long established phosphorylation of serine and threonine residues in the GS domain, the type
I receptor has also been shown to be phosphorylated at its tyrosine residues in response to TGFβ
(Lee et al., 2007). Taken together, these data suggest the importance of tyrosine phosphorylation
in the regulation of the TGFβ pathway.
It is not so surprising when we found out that during our primary screen, a large number
of protein tyrosine phosphatases came out (summarized in Table 5.1) contributing to a body size
phenotype in rrf-3 RNAi-hypersensitive background. With further epistatic analyses and reporter
assay, we find a line of protein tyrosine phosphatases involved in the regulation of the Sma/Mab
pathway. This might open up a new window of the regulatory mechanism of the TGFβ signaling.
As there are many more protein tyrosine phosphatases in the human genome than protein
serine/threonine phosphatases (107 and 30, respectively, Shi, 2009), we believe that the futher
investigation of the regulatory role of protein tyrosine phosphatases can add to the explanation
why this rather simple signal cascade can control such a broad range of cellular responses.

Table 5.1 The protein tyrosine phosphatase family members contribute to the
body size control in C. elegans

Body size phenotype
Sma
Lon

Gene identifier
C40A11.5
K09F6.3
C05B10.1
C17H12.3
C18E9.7
C24D10.1
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C33F10.8
C43E11.5
C46A5.1
F20H11.4
F25H5.7
F26A3.4
F36H1.3
F38H4.4
F44G4.8
F47B3.2
F54C8.4
F55F8.7
F57H12.5
M05D6.3
R06B10.1
R12E2.10
R155.3
T04F3.3
T20B6.1
T21E3.1
VW02B12L.2
Y5F2A.3
Y116A8C.37
ZK354.8
ZK484.7
ZK783.2
ZK809.1
Sma: small body size; Lon: long body size

Table 5.2 The protein tyrosine phosphatases play a role in the Sma/Mab pathway
regulation

Wormbase

rrf-3

annotation
C05B10.1
C17H12.3
C43E11.5

Lon
Lon
Lon

sma-

dbl-

lon-

RED-SMAD

6(wk7)

1(ctIs40)

2(e678)

reporter assay

NS
NS
NS

NS
NS
NS

NS
NS
NS

Stronger
Stronger
Stronger

Sequence
verified
ND
ND
+
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F38H4.4
F54C8.4

Lon
Lon

NS
NS

NS
NS

F57H12.5
K09F6.3

Lon
Sma

NS
NS

NS
NS

R155.3

Lon

NS

T04F3.3

Lon

NS

ZK354.8

Lon

NS

ZK484.7

Lon

NS

Enhanced
Lon
Enhanced
Lon
Enhanced
Lon
NS

ZK783.2

Lon

NS

Enhanced
Lon

NS
Enhanced
Lon
NS
NS
Enhanced
Lon
Enhanced
Lon
Enhanced
Lon
Enhanced
Lon
Enhanced
Lon

Stronger
Stronger

+
ND

Stronger
NS/a little bit
weaker
Stronger

ND
ND

NS/ a little bit
stronger
Stronger

ND

Stronger

ND

Stronger

+

+

ND
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Appendix
1. C. elegans ADAMTS ADT-2 regulates body size by modulating TGFβ signaling
and cuticle collagen organization (Fernando et al., 2011)

2. Using RNA-mediated interference feeding strategy to screen for genes involved in body
size regulation in the nematode C. elegans (Liang et al., 2013)
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a b s t r a c t
Organismal growth and body size are inﬂuenced by both genetic and environmental factors. We have utilized
the strong molecular genetic techniques available in the nematode Caenorhabditis elegans to identify genetic
determinants of body size. In C. elegans, DBL-1, a member of the conserved family of secreted growth factors
known as the Transforming Growth Factor β superfamily, is known to play a major role in growth control. The
mechanisms by which other determinants of body size function, however, is less well understood. To identify
additional genes involved in body size regulation, a genetic screen for small mutants was previously
performed. One of the genes identiﬁed in that screen was sma-21. We now demonstrate that sma-21 encodes
ADT-2, a member of the ADAMTS (a disintegrin and metalloprotease with thrombospondin motifs) family of
secreted metalloproteases. ADAMTS proteins are believed to remodel the extracellular matrix and may
modulate the activity of extracellular signals. Genetic interactions suggest that ADT-2 acts in parallel with or
in multiple size regulatory pathways. We demonstrate that ADT-2 is required for normal levels of expression
of a DBL-1-responsive transcriptional reporter. We further demonstrate that adt-2 regulatory sequences drive
expression in glial-like and vulval cells, and that ADT-2 activity is required for normal cuticle collagen ﬁbril
organization. We therefore propose that ADT-2 regulates body size both by modulating TGFβ signaling
activity and by maintaining normal cuticle structure.
© 2011 Elsevier Inc. All rights reserved.

Introduction
Body size is a fundamental feature of an organism critical to survival
and ﬁtness, yet the mechanisms underlying its regulation remain
incompletely understood. Existing studies show that body size is in part
genetically controlled (Oldham et al., 2000). For example, in Drosophila,
the insulin/insulin-like growth factor 1 (IGF1) signaling pathway
regulates body size, so that mutants are smaller than wild-type ﬂies
(Bohni et al., 1999; Leevers et al., 1996; Neufeld and Edgar, 1998). Flies
mutant for Drosophila S6 kinase (DS6K) and d-Myc also have slow
growth, reduced cell size and small body size (Gallant et al., 1996;
Johnston et al., 1999; Montagne et al., 1999). The Drosophila homolog of
the target of rapamycin (TOR) affects growth by modulating the activity
of DS6K. Mutant cells are small in size (Neufeld, 2003; Oldham et al.,
2000). In contrast, the Salvador–Warts–Hippo (SWH) pathway
represses tissue size. Lack of SWH pathway component activity results
in overgrowth of adult structures (Badouel et al., 2009; Tyler and Baker,
2007; Willecke et al., 2006).
⁎ Corresponding author at: Department of Biology, Queens College, CUNY, 65-30
Kissena Blvd., Flushing, NY 11367, USA. Fax: + 1 718 997 3445.
E-mail address: cathy.savagedunn@qc.cuny.edu (C. Savage-Dunn).
0012-1606/$ – see front matter © 2011 Elsevier Inc. All rights reserved.
doi:10.1016/j.ydbio.2011.01.016

In Caenorhabditis elegans, there are several known small body size
mutants. Components of the DBL-1 Transforming Growth Factor β
(TGF-β) pathway play a major role in the regulation of body size.
Mutations in any component of the pathway, dbl-1 (ligand), sma-6
(type I receptor), daf-4 (type II receptor), sma-2, sma-3, sma-4 (Smad
transcription factors) and sma-9 (transcription co-factor) result in
smaller than wild-type body size (Estevez et al., 1993; Krishna et al.,
1999; Liang et al., 2003; Savage-Dunn, 2005; Savage-Dunn et al., 2003;
Savage et al., 1996; Suzuki et al., 1999).
In addition to the DBL-1 pathway, other genes have been identiﬁed
that play less critical roles in regulation of body size. One such group is
genes that are expressed in sensory neurons, including che-2, che-3,
egl-4, tax-6 and cnb-1 (Bandyopadhyay et al., 2002; Fujiwara et al.,
2002; Kuhara et al., 2002). The che-2 and che-3 mutations cause small
body size due to defects in sensory perception. egl-4 (cGMP-Dependent
Protein Kinase) acts downstream of che mutants to regulate body size by
repressing the DBL-1 pathway (Fujiwara et al., 2002). tax-6 and cnb-1
encode the catalytic and regulatory subunits of calcineurin, respectively.
tax-6 interacts with kin-29 (ser/thr kinase) and mef-2 (MADS box
transcription factor) to regulate body size (Singaravelu et al., 2007).
Feeding defective mutants also have small body size. These include
pha-2 and pha-3 with abnormal pharyngeal anatomy, eat-1, eat-2, eat-3
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with reduced pumping rates and eat-10 with inefﬁcient pharyngeal
pumping (Morck and Pilon, 2006). Mutations of components of the
TORC2 complex result in small body size (Jones et al., 2009; Soukas et al.,
2009). Intriguing recent evidence implicates the cell death machinery in
the regulation of cell and body size (Chen et al., 2008). In addition,
mutations that affect the structure of the cuticle can change the body
size of the animal because the cuticle encapsulates the body. Some
examples are dpy-2, dpy-7, dpy-10, dpy-13, sqt-1, sqt-3 and lon-3. All of
these genes encode cuticular collagens (Johnstone et al., 1992; Kramer,
1994; Kramer and Johnson, 1993; Kramer et al., 1988; Levy et al., 1993;
Nystrom et al., 2002; Suzuki et al., 2002; van der Keyl et al., 1994;
von Mende et al., 1988). Finally, mutations in a small number of genes
which have yet to be assigned to a particular pathway, including sma-1
(βH-spectrin), sma-5 (MAP kinase BMK1/ERK5 homolog) and rnt-1
(RUNX family transcription factor), also cause small body size (Ji et al.,
2004; McKeown et al., 1998; Watanabe et al., 2005).
To understand the genetic basis of body size regulation, a forward genetic screen for small body size mutants was carried out
(Savage-Dunn et al., 2003). In that screen, alleles of many of these
genes were identiﬁed. Furthermore, one of the novel small body size
mutants isolated was sma-21, which we now show is allelic with
ADAMTS family member adt-2.
ADAMTS (a disintegrin-like and metalloprotease with thrombospondin type I motif) are secreted metalloproteases that bind to the
extracellular matrix (ECM) (Kuno and Matsushima, 1998; Porter et al.,
2005; Tang, 2001). ADAMTS are related to the ADAM (a disintegrin and
metalloprotease) subfamily of transmembrane proteins. Both ADAM
and ADAMTS proteins are Zn dependent metalloproteases (Jones and
Riley, 2005; Kaushal and Shah, 2000; Stocker et al., 1995). In mammals,
the ADAMTS proteases are believed to function in ECM assembly
(procollagen N-proteinases: ADAMTS-2, -3 and -14) and ECM degradation (aggrecanases: ADAMTS-1, -4, -5, -8, -9 and -15) (Colige et al., 1995,
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1997; Collins-Racie et al., 2004; Fernandes et al., 2001; Kuno et al., 2000;
Somerville et al., 2003; Tortorella et al., 2000, 2005; Wang et al., 2003).
In C. elegans, some of these proteases are involved in organogenesis by
remodeling the ECM. For example, GON-1 and MIG-17 are involved in
distal tip cell migration in gonad development (Blelloch and Kimble,
1999; Ihara and Nishiwaki, 2007). Another protease ADT-1 is involved in
ray morphogenesis by rapid remodeling of ECM (Kuno et al., 2002).
In this study we describe the role of C. elegans ADAMTS gene adt-2
in the control of body size. Genetic interactions show that adt-2 is
likely involved in multiple pathways that regulate body size. We show
that ADT-2 is synthesized in glial cells of sensory neurons and in the
vulva, and is required to promote DBL-1 signaling activity and for
normal cuticle structure.
Results
Isolation of sma-21 mutants
To identify genes required for body size regulation, a forward genetic
screen for small body size mutants was carried out (Savage-Dunn et al.,
2003). In that screen, N2 hermaphrodites were mutagenized with ethyl
methanesulfonate (EMS) and the F2 progeny worms were screened for
small body phenotype. In the screen, sma-20 mutants were identiﬁed. In
the course of mapping, we found that the sma-20 strain has two
mutations, sma-20(wk31) and sma-21(wk156). Furthermore, 23 semismall segregants were isolated from the double mutant strain and it was
found that they were all allelic to sma-21. This ﬁnding led us to the
conclusion that sma-21 regulates body size, and that sma-20 is an
enhancer of the sma-21 phenotype with no apparent phenotype on its
own. All of the analyses in this paper were performed with a sma-21
(wk156) segregant from which the sma-20 enhancer mutation was
outcrossed.

Fig. 1. sma-21 encodes ADT-2. (A,B,C) RNAi inactivation of adt-2 results in small body size. K09F5.1(RNAi) treated worms are indistinguishable from control worms. rrf-3 RNAi
hypersensitive strain is used for body size measurements. (D,E,F) Fosmid WRM0636aH08 containing adt-2 gene rescues the body size of sma-21(wk156). A,B,D and E are adult
worms photographed at the same magniﬁcation. Body length was measured in adult worms. Each value represents a mean of 30 – 60 worms. Error bars indicate the standard
deviation. Scale bars = 0.2mm. **indicates pb0.01.
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Table 1
Amino acid identity of C. elegans of ADT-2 to mammalian and C. elegans ADAMTS.
Calculated using Clustalw.
Catalytic domain First TSP type 1 motif Zn binding motif
C. elegans GON-1
C. elegans ADT-1
Mouse ADAMTS-1
Human ADAMTS-4
Human ADAMTS-5
Human ADAMTS-2
Human ADAMTS-3
Human ADAMTS-14

26
41
21
25
22
29
26
25

35
37
33
33
32
37
35
32

33
36
36
54
31
36
36
36

sma-21 encodes an ADAMTS (disintegrin and metalloprotease with
thrombospondin repeats) family member ADT-2
We used single nucleotide polymorphism (SNP) mapping (Davis
et al., 2005) to locate sma-21 on the X chromosome in the region
between 7,439,984 (cosmid C01C10) and 7,982,355 (cosmid F45E1).
Then, we employed array comparative genomic hybridization (aCGH)
to identify any polymorphisms in this region. An oligonucleotide chip
spanning this region was designed. This was hybridized with sma-21

and wild-type genomic DNA at Roche NimbleGen (Maydan et al.,
2009). This analysis identiﬁed two polymorphisms in the sma-21
mutant: one in K09F5.1 and one in adt-2. Sequence analysis of PCR
fragments in sma-21 veriﬁed the two SNPs: one at 7,590,038 bp (G to
A) in the adt-2 gene and the other at 7,740,620 (G to A) in K09F5.1. To
determine which of these mutations is responsible for the small body
size phenotype in sma-21, we used RNAi and transformation rescue.
We inactivated the corresponding genes by feeding N2 (wild type) and
rrf-3 (RNAi hypersensitive) worms on adt-2 RNAi and K09F5.1 RNAi
plates (Kamath et al., 2001). adt-2 RNAi fed worms are small unlike the
K09F5.1 RNAi (Fig. 1). Then, we introduced fosmid clones containing
adt-2 wild-type sequences into sma-21 mutants by microinjection
(Mello et al., 1991). The fosmid clone WRM0636aH08 which contains
the full-length adt-2 wild-type gene rescues the body size of sma-21
(wk156) (Fig. 1). Finally, we performed a complementation test
between sma-21 and a deletion allele of adt-2(tm975) obtained from
the CGC. The complementation test shows that these two mutations
fail to complement for body size. Putting all the data together, we can
conclude that sma-21 encodes adt-2. We will therefore refer to sma-21
as adt-2.
In order to verify the exon–intron structure of adt-2, we sequenced
cDNA clones obtained from Dr Yuji Kohara. Sequencing of multiple
cDNA clones gave no evidence for alternative splicing. The sequence of

Fig. 2. Structure of the ADT-2 protein. (A) Domain organization of ADT-2 protein. Domain organization of mammalian ADAMTS-2 is shown for comparison (predicted by SBASE and
SignalP 3.0 Server). (B) Amino acid sequence of ADT-2. Different domains are highlighted. In red is the signal sequence; in violet, the prodomain; in brown, the catalytic domain.
Underlined is the Zn binding motif. In green is the conserved methionine residue downstream of the metal binding motif which forms ‘Met turn’ (Porter et al., 2005). In yellow is the
cysteine-rich domain. Thrombospondin type I-like repeats are highlighted in blue. The location of the deletion in tm975 and the missense mutation (Gly364-Ser) in wk156 are
indicated by a shaded box and an asterisk, respectively. (C) Zinc-binding motif and Met turn of C. elegans ADT-2 are aligned with other mammalian and C. elegans ADAMTS family
members. The conserved zinc-binding motif and methionine residue downstream of the metal binding site are shaded. Asterisks indicate conserved amino acids. The glycine in red is
the conserved residue mutated in adt-2(wk156). (D) Phylogenetic tree showing relationships between C. elegans and human ADAMTS sequences (constructed using BioEdit
sequence Alignment Editor and MEGA 4.0.2). The numbers above the nodes indicate the percent bootstrap values in 500 replicates of the data.
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Fig. 3. Phenotypes of adt-2 mutants. (A) adt-2(wk156) mutant has small body size. Growth curve of adt-2 showing reduced growth rate compared to wild-type N2 worms. Each time point represents a mean of 25–50 animals. Error bars
indicate the standard deviation. Body size of adt-2 mutant at each point except 24 h is signiﬁcantly different from that of wild-type. (B,C) Lethal phenotype of adt-2(tm975) deletion homozygotes. Images show an unhatched embryo (threefold stage; B) and a partially hatched larva (C). D) Reduced lifespan of adt-2 mutants. A Kaplan–Meier survival curve shows the lifespan of wild-type N2 (blue; median survival 16 days), mutant adt-2(wk156) (brown; median survival 10 days;
logrank statistical comparison p b 0.0001 relative to N2), adt-2(RNAi) (orange; median survival 8 days; logrank statistical comparison p b 0.0001 relative to N2) and adt-2(RNAi) initiated in adulthood (green; median survival 14 days; logrank
statistical comparison p b 0.0001 relative to N2). For each strain, n = 120 worms.
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EST yk1586e04 contains the full-length transcript revealing that adt-2
consists of 20 exons (exon 1 is non-coding) that encode a protein of
1020 amino acids. ADT-2 belongs to the ADAMTS family of secreted
extracellular metalloproteases. These proteins bind to extracellular
matrix (ECM) and are believed to be involved in remodeling of the
ECM (Porter et al., 2005). As shown in Table 1, the catalytic domain of
ADT-2 shows 21% to 41% homology to other ADAMTS family
members. These proteins are comprised of several domains. Starting
with the N terminus, ADT-2 has a signal peptide (predicted by SignalP
3.0 Server); a catalytic domain with a reprolysin- type zinc-binding
motif, HEX1X2HX3X1GX1XHD [where X1 is typically hydrophobic aa,
X2 is glycine or a hydrophobic aa and X3 is asparagine (http://www.
lerner.ccf.org/bme/apte/adamts/domain_organization.php)]; a cysteinerich domain; a central TS (thrombospondin type I-like) domain and six
C-terminal TS repeats (predicted by SBASE release 14, Sept 2006)
(Fig. 2A). The domain organization of mammalian ADAMTS-2 is shown
for comparison (Fig. 2A). Table 1 shows the amino acid identity in the
zinc-binding motif, catalytic domain and in the ﬁrst thrombospondin
type I-like repeat of C. elegans ADT-2 compared to mammalian and
C. elegans ADAMTS. The metalloprotease domain of ADT-2 shows the
highest similarity to ADAMTS-2, -3, and -14 among mammalian
ADAMTS family members (Table 1 and Fig. 2D).
adt-2(wk156) is a missense mutation that changes a conserved
glycine residue to a serine (highlighted in red in Fig. 2C) within the
metal binding motif. Conservation of this glycine residue suggests that
it is functionally important. adt-2(tm975) has a deletion of 475 bp
(WormBase; Fig. 2B) which deletes 92 amino acids within the catalytic
domain including the metal binding motif. adt-2(tm975) is lethal.
Homozygous adt-2(tm975) mutants die at the 3-fold stage of embryogenesis or during hatching (Figs. 3B and C).
Phenotypic characterization of adt-2
To characterize the body size phenotype of adt-2(wk156), we
created growth curves that indicate the body length of wild-type N2
worms and adt-2(wk156) worms at various times after egg collection
(Fig. 3A). Newly hatched adt-2 mutant larvae have the same body
length as control animals, similar to dbl-1 pathway mutants. adt-2
mutant worms grow more slowly after 24 hours resulting in adult
worms with about a 20% reduced body length when compared to wild
type. Interestingly, adult adt-2 mutants show a signiﬁcant decrease in
body length between 96 and 120 h, whereas wild-type animals continue to grow larger during adulthood. The reduction in body length
in adt-2 mutants suggests that the gene is required for maintenance
of body length as well as for increase in body length during growth
stages.
We have also examined the body width of adt-2 mutants. Typical
small mutants, such as those defective in the DBL-1 pathway, have
reduced width as well as reduced length. In contrast, dumpy mutants,
such as those defective in some cuticle collagens, have reduced length

but not reduced width. adt-2(wk156) mutants show a signiﬁcantly
increased body width, 0.072 mm +/− 0.005 mm vs 0.066 mm +/
− 0.005 mm for N2 wild-type controls grown concurrently under the
same conditions, p b 0.01 (see also Fig. 1E). In contrast, adt-2(RNAi)
animals show a signiﬁcantly reduced body width, 0.072 mm +/
− 0.006 mm vs 0.089 mm+/− 0.006 mm for control animals grown
concurrently under the same conditions, p b 0.01 (see also Fig. 1B). Thus,
the partial loss-of-function adt-2(wk156) mutant resembles a dumpy
mutant, whereas more severe loss-of-function due to RNAi inactivation
results in a more characteristic small phenotype.
We next evaluated the effects of adt-2 on lifespan. Both adt-2
(wk156) and adt-2(RNAi) have signiﬁcantly reduced lifespans compared to wild type, with a median survival of 10 and 8 days from
adulthood, respectively, compared with 16 days for wild type
(Fig. 3D). Since early lethality could be due to developmental defects
associated with adt-2 loss-of-function, we also measured lifespan of
animals grown under normal conditions until adulthood and then
transferred to adt-2(RNAi) conditions. These animals also show
reduced adult longevity, with a median survival of 14 days and a
maximum survival reduced from 21 days to 18 days (Fig. 3D). Overall,
the median lifespan of adt-2 mutants and adt-2(RNAi) under
conditions tested is reduced by 13% to 50% relative to wild type.
Thus, adt-2 activity is required to promote normal adult longevity.
The reduction in body length of adt-2 mutants could be due to
decreased cell number, cell size or alterations in cellular or extracellular morphology. In order to determine which cause is responsible
in this case, we ﬁrst examined the number of seam cells, the number of
intestinal cells, and the number of hypodermal nuclei in wild-type and
adt-2 mutant animals. The number of seam cells was measured using
the seam cell marker::GFP reporter, and found to be not signiﬁcantly
different in adt-2(wk156) or adt-2(RNAi) compared to controls
(Table 2). DAPI staining was done in order to count intestinal nuclei,
which are the same in adt-2(wk156) and adt-2(RNAi) compared with
controls (Table 2). We also counted the number of nuclei in the
hypodermis of fourth larval stage (L4) worms of adt-2(wk156), adt-2
(RNAi), and control animals. Hypodermal nuclei were counted using
the dpy-7p::2Xnls::yfp marker, which is expressed in hypodermal cells
beginning at the L1 stage (Myers and Greenwald, 2005). The number
of hypodermal nuclei is not signiﬁcantly different in adt-2 mutants
compared to control animals (Table 2). For comparison, we determined the number of hypodermal nuclei in dbl-1 mutants, which is
also not signiﬁcantly different from wild type (114.6 +/− 9.4). These
results are consistent with previous reports that DBL-1 pathway
mutants have normal numbers of hypodermal nuclei (Nagamatsu and
Ohshima, 2004).
We also measured the dimensions of two accessible tissues (seam
cells and the pharynx) in adt-2 and wild type. We crossed an ajm-1::
gfp seam cell marker into adt-2(wk156) or fed the strain adt-2(RNAi)
bacteria and observed ﬂuorescence in the L3 larval stage. The ajm-1::
gfp marker localizes at the adherens junctions in the seam cells

Table 2
Cell and nuclei measurements of adt-2 and wild-type worms.

Seam cell number
(Adult)
Intestinal nuclei number
(Adult)
Hypodermal nuclei number
(L4)
Seam cell perimeter (mm)
(L3)
Pharynx length (mm)
(L3)
Body size (mm)
(L3)
**p b 0.01 compared to control.

N2

adt-2(wk156)

RNAi control

adt-2(RNAi)

16 +/− 0
(n = 30)
31.4 +/− 1.2
(n = 31)
116.3 +/− 11.9
(n = 33)
0.073 +/− 0.011
(n = 78)
0.109 +/− 0.006
(n = 18)
0.651 +/− 0.053
(n = 23)

16 +/− 0
(n = 30)
31.5 +/− 1.4
(n = 38)
114.1 +/− 10.7
(n = 31)
0.067** +/− 0.011
(n = 76)
0.108 +/− 0.009
(n = 18)
0.575** +/− 0.065
(n = 27)

16.1 +/− 0.7
(n = 10)
32.7 +/− 1.4
(n = 10)
145.4 +/− 6.3
(n = 5)

16.2 +/− 0.4
(n = 20)
33.4 +/− 1.0
(n = 20)
145.9 +/− 4.0
(n = 10)
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(Mohler et al., 1998). The pharynx length and body length of the same
L3 worms were also measured. The length measurements for adt-2
(RNAi) animals are not signiﬁcantly different from controls at the L3
stage (data not shown). The perimeters of individual seam cells and
the overall body length of adt-2(wk156), however, are reduced
signiﬁcantly compared to wild-type animals, while the length of the
pharynx is not affected (Table 2). These data are consistent with the
hypothesis that adt-2 mutants are smaller at least partly due to
decreased cell size or altered cell morphology, rather than decreased
cell number. Our previous analysis of DBL-1 pathway mutants
similarly revealed size reductions in the seam cells but not in the
pharynx (Wang et al., 2002). Thus, the adt-2 size defects are similar to
those seen in mutants of the DBL-1 signaling pathway.
Genetic interactions of adt-2 and other body size mutants in C. elegans
The DBL-1 pathway plays a major role in body size regulation in
C. elegans. Mutations in any components of the pathway, dbl-1
(ligand), sma-6 (type I receptor), daf-4 (type II receptor), sma-2, sma-
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3, sma-4 (Smad transcription factors), sma-9 (transcription co-factor)
will result in smaller bodies than wild type (Estevez et al., 1993;
Krishna et al., 1999; Liang et al., 2003; Savage-Dunn, 2005; SavageDunn et al., 2003; Savage et al., 1996; Suzuki et al., 1999). Double
mutants were created in order to determine the relationship between
adt-2 and dbl-1 pathway components. The dbl-1 pathway mutants we
used for this are null or strong alleles. Double mutants of adt-2
(wk156) combined with dbl-1(wk70), sma-6(wk7), daf-4(e1364),
sma-2(e502), sma-3(wk30), sma-4(e729) or sma-9(wk55) have a
smaller body size than the respective single mutants (Fig. 4A),
indicating that adt-2 may act in a parallel pathway to regulate body
size. To further validate this result, we looked at the dbl-1 overexpression [dbl-1(++)] phenotype in the adt-2 mutant background.
dbl-1(++) results in a long (Lon) body phenotype in an otherwise
wild-type background, but the small (Sma) phenotypes of sma-2,
sma-3, sma-4, sma-6 and daf-4 are epistatic to the Lon phenotype of
dbl-1(++). This epistasis places the activity of these sma genes
downstream of the DBL-1 ligand activity (Suzuki et al., 1999). We fed
dbl-1(++) worms on adt-2 RNAi plates. However, rather than the

Fig. 4. Genetic interactions of adt-2 and other small body size mutants in C. elegans. In each graph ﬁrst two bars represents N2 and adt-2(wk156). Subsequent bars represent the
indicated single mutant and corresponding double mutant with adt-2(wk156) or adt-2(RNAi). Data are shown as a percentage of wild-type body length. Each bar represents a mean
of more than 27 adult animals measured at 96 h after embryo collection (except daf-4 and daf-4;adt-2 which were grown at 15°C for 144 h) . Error bars indicate the standard
deviation. ** indicates p b 0.01 for the pairwise comparison between the single mutant and the corresponding double mutant with adt-2.
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Table 3
Epistasis analysis between adt-2 and dbl-1 overexpression.
Genotype

Body length in adult animals

n

N2
adt-2
ctIs40[pTG96(sur-5::gfp); dbl-1(++)]
adt-2; ctIs40[pTG96(sur-5::gfp);dbl-1(++)]a,b

1.193 +/− 0.065
1.004 +/− 0.048
1.336 +/− 0.069
1.177 +/− 0.07

33
28
33
33

a
b

Value is not signiﬁcantly different from N2, p N 0.05.
Value is signiﬁcantly different from both adt-2 and ctIs40, p b 0.0001.

expected Sma phenotype, if the adt-2 gene activity were downstream,
the body length is intermediate (Table 3). This is evidence that adt-2
acts at least partially independently of the DBL-1 pathway.
To determine whether adt-2 interacts with other pathways that
regulate body size, we next tested mutants in sensory processing. che2 and che-3 mutants have impaired sensory cilia and therefore defects
in sensory perception. They also have a small body size phenotype.
EGL-4 cGMP-dependent protein kinase acts downstream of che genes
to regulate body size by repressing the dbl-1 pathway (Fujiwara et al.,
2002). The tax-6 and cnb-1 genes encode calcineurin A and B subunits.
Both tax-6 and cnb-1 are expressed in sensory neurons. Mutations in
these genes cause pleiotropic defects including small body size and

defects in sensory neuronal behavior (Bandyopadhyay et al., 2002;
Kuhara et al., 2002). cnb-1 also has a transparent appearance because
of thinning of the cuticle (Bandyopadhyay et al., 2002). In order to see
whether adt-2 functions in the chemosensory pathways, double
knockdowns between adt-2 and egl-4, che-2, tax-6, and cnb-1 were
made by combining existing chromosomal mutations and RNAi
inactivation of adt-2. Alleles chosen were likely molecular nulls
or the characterized reference alleles for each gene. The egl-4(n477);
adt-2(RNAi) double knockdowns have an intermediate body size
compared to egl-4 and adt-2 single mutant animals. The che-2(e1033);
adt-2(RNAi), tax-6(ok2065);adt-2(RNAi), and cnb-1(p675);adt-2
(RNAi) double knockdowns also show additive effects (Fig. 4B). The
feeding defective mutants pha-2 and pha-3 (Morck and Pilon, 2006)
were also analyzed, and found to have additive effects on body size with
adt-2 (Fig. 4B). A deletion allele of pha-2 is lethal, precluding the
possibility of testing for body size phenotypes in the pha-2 homozygous
mutant background.
To test whether adt-2 functions in the same pathways as rnt-1 and
sma-1, rnt-1(ok351);adt-2(wk156) and sma-1(e30);adt-2(wk156) double mutants were constructed, using a deletion allele of rnt-1 and a
nonsense allele of sma-1. The rnt-1 gene is the C. elegans homologue of
mammalian RUNX transcription factors (Ji et al., 2004). sma-1 encodes

Fig. 5. Expression of RAD–SMAD, a DBL-1 pathway transcriptional reporter. GFP expression was assessed at the L2 stage in hypodermal nuclei. (A, B) Wild-type strain fed control or adt-2
(RNAi) bacteria; (C, D) lon-2 mutant fed control or adt-2(RNAi) bacteria; (E, F) dbl-1 mutant fed control or adt-2(RNAi) bacteria. Body length of the same strains was measured in adulthood,
and the mean length shown in mm in each panel. In each case, the adt-2(RNAi) treatment reduced body size compared to the respective control strain signiﬁcantly (pb 0.01).
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βH-spectrin (McKeown et al., 1998). Mutations in these genes cause
a small body size phenotype. Double mutants of rnt-1(ok351);adt-2
(wk156) and sma-1(e30);adt-2(wk156) show additive effects
(Fig. 4C). Thus, we can conclude that adt-2 acts independently of all
tested pathways, or is involved in multiple pathways that regulate
body size.
Since adt-2 may act in multiple pathways to regulate body size, we
tested whether it has an effect on a DBL-1 pathway transcriptional
reporter. The RAD–SMAD reporter (a generous gift of Jun Liu) consists
of tandem Smad GTCT binding sites driving expression of nuclearly
localized GFP (Tian et al., 2010). GFP expression levels from this
construct are positively regulated by DBL-1 signaling (Tian et al., 2010)
(Figs. 5A, C, E). We tested whether RAD–SMAD expression is regulated
by adt-2(RNAi). adt-2(RNAi) reduces the expression of RAD–SMAD in an
otherwise wild-type background (Figs. 5A and B). LON-2 is a glypican
that negatively regulates DBL-1 activity (Gumienny et al., 2007). In the
lon-2 mutant background, RAD–SMAD expression is increased (Tian
et al., 2010) (Fig. 5C), and this expression is also reduced by adt-2(RNAi)
(Fig. 5D). In the dbl-1 mutant background, RAD–SMAD expression is
reduced to a few dimly ﬂuorescing nuclei in the posterior (Fig. 5E) and
this expression is not diminished further by adt-2(RNAi) (Fig. 5F). Thus,
adt-2 is a positive regulator of a DBL-1-responsive reporter. Furthermore, unlike the additive effect on body size regulation, the effects of
dbl-1 and adt-2 on RAD–SMAD regulation are not additive, indicating
that ADT-2 regulates this reporter via the DBL-1 pathway. We therefore
conclude that ADT-2 directly or indirectly regulates DBL-1 signaling
activity.
adt-2 may regulate body size in part by modiﬁcation of the external
cuticle
Our results thus far indicate that ADT-2 may regulate body size in
part by modulation of DBL-1 signaling activity, but also in part
independently of the DBL-1 pathway. Since ADAMTSs are known to
process ECM proteins, we considered whether adt-2 might regulate
body size by targeting the cuticle. The cuticle of C. elegans is a collagencontaining extracellular matrix that surrounds the body and lines the
four major openings to the exterior (pharynx, excretory pore, vulva, and
anus). The cuticle is known to play a role in determining body size and
morphology. In particular, the genes dpy-2, dpy-7, dpy-10, dpy-13, sqt-1,
sqt-3 and lon-3 that encode cuticular collagens are required for normal
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body length (Johnstone et al., 1992; Kramer, 1994; Kramer and Johnson,
1993; Kramer et al., 1988; Levy et al., 1993; Nystrom et al., 2002; Suzuki
et al., 2002; van der Keyl et al., 1994; von Mende et al., 1988). In addition,
the adt-2(wk156) mutant phenotype is similar to the dumpy phenotypes displayed by some of these mutants. To test the hypothesis that
adt-2 functions via the cuticle, we ﬁrst determined the gene's expression
pattern using a transcriptional fusion of GFP to putative adt-2 promoter
sequences. No expression from the transgene is seen in embryonic
stages. It is possible that adt-2 is maternally provided for embryonic
development, but that adt-2p::gfp expression is silenced in the maternal
germline. GFP expression is detected in glial cells associated with
amphid, phasmid, labial and posterior deirids (PDE) sensory neurons as
early as the L1 stage and continuing throughout larval development
(Figs. 6A–C). Expression is also seen in vulval tissue in L4 and adult
animals (Fig. 6D). We note that these glial and vulval cells are in close
association with the external cuticle, so it is possible that ADT-2 exerts
its inﬂuences by proteolytic processing of cuticle proteins such as
collagen. It is also possible that adt-2 is expressed in additional locations,
if this construct does not contain all of the sequences necessary for
normal expression of adt-2.
To determine whether ADT-2 is secreted to the cuticle, we examined
the localization of an ADT-2::GFP fusion protein. We used fosmid
recombineering (Tursun et al., 2009) to insert GFP coding sequences at
the C-terminal end of the adt-2 coding sequence. Mixtures of
recombineered fosmids were injected into adt-2(wk156) animals,
yielding a total of nine independent transgenic lines. Six of nine lines
rescue the small body size phenotype of adt-2(wk156), indicating that
the GFP fusion is functional. Nonetheless, no consistent green
ﬂuorescence above background levels is seen in these lines (data not
shown). The lack of GFP could indicate that ADT-2 protein does not
accumulate to a high level, or that the C-terminus is proteolytically
processed and degraded.
To test whether ADT-2 acts to regulate cuticle collagen organization, we used a COL-19::GFP protein fusion (Thein et al., 2003) to
visualize the cuticle collagen ﬁbrils in adt-2 mutant and RNAi animals.
This reporter construct is expressed in annuli and lateral alae of the
adult cuticle [(Thein et al., 2003); Fig. 7A]. In adt-2(wk156) mutants,
which have the least severe body size phenotype, no signiﬁcant
disruption of the COL-19::GFP organization is observed. In these
mutants, the annuli are constricted (Table 4), which could be either a
primary or secondary defect, but is also seen in some collagen mutants

Fig. 6. Expression pattern of an adt-2 reporter construct adt-2p::gfp. adt-2 is expressed in the glial cells of amphid and labial neurons (A), phasmids (B), and postdeirid (C) and in the vulva (D).
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Fig. 7. Aberrant COL-19::GFP localization in adt-2 mutants. (A,C,E) COL-19::GFP expression. (B,D,F) Nomarski microscopy image of cuticular alae. In wild-type animals, COL-19::GFP
fusion protein is expressed in annuli extending over most of the dorsal and ventral cuticle (A). The cuticle of adult wild-type hermaphrodite shows lateral alae with three
characteristic ridges (B). RNAi inactivation of adt-2 causes an expanded region of disruption in the lateral cuticle (double headed arrow; C). Patches of disorganization of the annuli
are also evident in the adt-2(tm975/wk156) adult worms (E). Nomarski microscopy images of the cuticle of adt-2(tm975/wk156) hermaphrodites show abnormal numbers of alae
(arrowheads; four in D and two in F), as well as discontinuous alae (D; arrows from ﬁrst asterisk mark region in which third ridge from top is discontinued; second asterisk marks
region in which top ridge is discontinued, transitioning from four alae to three alae).

(Thein et al., 2003). As shown in Fig. 7C, animals treated with adt-2
(RNAi) show signiﬁcant disruptions of the lateral cuticle overlying the
seam cells. We also detect constrictions of the annuli in adt-2(RNAi)
worms (Fig. 7C and Table 4). We analyzed COL-19::GFP localization in
adt-2(tm975/wk156) transheterozygous animals, revealing patches of
disorganized annuli (Fig. 7E) and structural defects in the alae. The
defects are discontinuous alae and alae with two or four ridges as
compared to three ridges in the wild-type worms (Figs. 7B, D and F).
These disruptions may partially explain the reduced body size in adt-2
mutants and knockdowns.
Discussion
sma-21, a gene required for normal body size in C. elegans, encodes ADT-2
ADAMTS secreted metalloprotease
To characterize the genetic regulation of body size, we undertook the
molecular cloning of sma-21, a gene required for normal larval and adult
body size in the nematode C. elegans. Four independent pieces of
evidence demonstrate that sma-21 encodes ADT-2. First, sma-21
mutants contain a missense mutation in a conserved glycine residue
in the catalytic domain of ADT-2. Second, inactivation of ADT-2 by RNAi
phenocopies the small body size defect of sma-21 mutants. Third,
genomic clones containing adt-2 are sufﬁcient to rescue the body size
defect of sma-21 mutants. Fourth, a lethal deletion allele of adt-2 fails to
complement sma-21(wk156) for the body size defect.
adt-2 mutants and knockdowns display a graded series of defects.
The original wk156 mutation likely results in a partial loss-of-function,
since it causes a mild body size phenotype that is enhanced in trans
with a deletion allele. The wk156 mutational lesion results in an amino
acid substitution for a conserved glycine residue in the zinc-binding

motif of the catalytic domain. The resulting mutant protein apparently
retains partial activity. Knockdown of adt-2 by RNAi causes a more
severe body size phenotype than in the wk156 mutant, as well as some
lethality. Finally, the deletion allele tm975, which removes a large part
of the catalytic domain including the metal binding motif, causes late
embryonic lethality.
The molecular identiﬁcation of SMA-21/ADT-2 demonstrates a role
for ADAMTS function in the regulation of body size in C. elegans. This
function in body size regulation may be a conserved activity for ADAMTS
proteins. Consistent with this model, ADAMTS mutations and variants
are associated with normal and pathological variations in human height.
For example, ADAMTS2 is associated with connective tissue disorders
such as EDS (Ehlers–Danlos syndrome) in humans and with dermatosparaxis in cattle. Both disorders are characterized by fragility of skin and
short stature (Colige et al., 1999; Lenaers et al., 1971). A mutation in
ADAMTS10 is associated with Weill–Marchesani syndrome (WMS), a
disorder that is characterized by the short body size, short ﬁngers and
toes, joint stiffness and eye anomalies (Dagoneau et al., 2004). In
addition, a mutation in ADAMTSL2 (ADAMTS-like2) leads to geleophysic
dysplasia, a condition characterized by short stature and digit
abnormalities (Le Goff et al., 2008). Finally, gene variants in human
ADAMTS10, ADAMTS17 and ADAMTSL3 (ADAMTS-like3) are associated
with variation in human height (Gudbjartsson et al., 2008; Lettre et al.,
2008; Weedon et al., 2008).
ADT-2 is required for normal cuticle collagen ﬁbril structure and DBL-1
signaling activity
In mammals, ADAMTS proteases can be divided into two classes:
those involved in ECM assembly (procollagen N-proteinases:
ADAMTS-2, -3 and -14) and those involved in ECM degradation

Table 4
adt-2(wk156) and adt-2(RNAi) worms have constricted annuli.
Genotype

RNAi treatment

Distance between annuli (μm)

Number of annuli

Number of worms

kaIs12[COL-19::GFP]
kaIs12[COL-19::GFP];adt-2(wk156)
kaIs12[COL-19::GFP]
kaIs12[COL-19::GFP]

None
None
Empty vector control
adt-2(RNAi)

1.809 +/− 0.18
1.478 +/− 0.14**
1.656 +/− 0.20
1.437 +/− 0.16**

390
688
459
690

15
20
17
21

**p b 0.01.
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(aggrecanases: ADAMTS-1, -4, -5, -8, -9 and -15). ADT-2 is one of four
members of the ADAMTS family present in C. elegans. Two of these,
GON-1 and MIG-17, are more similar to the aggrecanases involved in
ECM degradation. These two proteins are involved in cell migrations
during organogenesis, and may function by locally degrading the
basement membrane ECM. In contrast, ADT-1 and ADT-2 are more
similar to the collagenases that are required for ECM assembly. ADT-1
is required for the morphogenesis of male copulatory organs, a process
that requires rapid remodeling of the ECM.
In C. elegans one ECM tissue, the cuticle, plays a major role in
determining body size due to the fact that it encapsulates C. elegans.
adt-2 mutants show a series of defects in the cuticle. We have
observed the COL-19::GFP collagen fusion protein marker in adt-2
mutant and RNAi backgrounds, and found that the recruitment of this
collagen fusion protein into ﬁbrils in the cuticle is aberrant. We see
major disruptions of the COL-19-containing ﬁbrils, particularly in the
lateral cuticle underlying the alae. These defects are associated with
shorter distances between the rings of annuli indicating excessive
longitudinal constriction of the cuticle. Defects in the alae can also be
seen by Nomarski DIC microscopy, including the presence of two or
four lateral ridges instead of the normal three, and the presence of
short discontinuities in the alae ridges. These defects are reminiscent
of defects reported in a subset of cuticle collagen mutants such as
dpy-5, dpy-13, and bli-1, and in col-19(RNAi) animals. Interestingly,
adt-2 was also previously identiﬁed in an RNAi screen for genes
required for molting of the cuticle (Craig et al., 2007; Frand et al.,
2005). Taken together, these results are consistent with a focus of
action for ADT-2 in the cuticle. Due to the defects in the cuticle of adt-2
mutants, the cuticle may not be able to maintain its integrity, which
leads to the resultant defect in body size. Also, adt-2(wk156) mutants
lose length rather than growing during adulthood, which could be
caused by a lack of cuticle integrity. These defects in the cuticle can
also explain the reduced lifespan of adt-2 mutants as an increased
vulnerability to injuries and infection.
To test for an inﬂuence of ADT-2 on the DBL-1/BMP signaling
pathway, the major size regulating pathway in C. elegans, we employed
a DBL-1-responsive transcriptional reporter, RAD–SMAD (Tian et al.,
2010). Intriguingly, adt-2 inactivation leads to a reduction in expression
of this reporter, indicating that ADT-2 also regulates body size in part by
direct or indirect modulation of DBL-1 signaling. Since TGFβ ligands are
often secreted in inactive forms that must be activated by proteolysis
(Lawrence, 2001), it possible that ADT-2 is directly involved in
activation of DBL-1. Based on the other roles of ADT-2 in the cuticle,
however, we ﬁnd it more likely that ADT-2 plays an indirect role.
Consistent with this hypothesis, ECM is known to inﬂuence the activity
of signaling pathways; for example, ECM collagens act as regulators
of BMP signaling in Drosophila (Wang et al., 2008). It is therefore
possible that ADT-2 modiﬁcation of the ECM leads to changes in DBL-1
bioavailability.
Materials and methods
Strains
C. elegans strains were grown at 20 °C using standard methods
(Brenner, 1974), except for daf-4, which was grown at 15 °C to
prevent constitutive Dauer formation. All of the analyses reported
here were performed with a sma-21(wk156) segregant from which
the sma-20 enhancer mutation was outcrossed. In addition to strains
generated in this study the following strains were used:
N2 and HA (wild type)
LG I: rnt-1(ok351)
LG II: cnb-1(ok276)
LG III: sma-2(e502), sma-3(wk30), sma-4(e729), daf-4(e1364)
LG IV: tax-6(ok2065), egl-4(n477), pha-3(ad607)
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LG V: dbl-1(wk70), sma-1(e30), him-5(e1490)
LG X: adt-2(tm975) obtained from Dr. Shohei Mitani, National
Bioresource Project for the nematode, Tokyo Women's Medical
University School of Medicine, Japan; sma-9(wk55), che-2(e1033),
pha-2(ad472).
Transgenics: dbl-1(ctIs40) (Suzuki et al., 1999); TP12 [COL-19::GFP]
obtained from Dr. Antony Page; wIs51 [SCM::GFP, unc-119(+)]; jcIs1
[ajm-1::gfp] obtained from Dr. Jeff Simske; arIs99 [dpy-7p::2Xnls::yfp]
obtained from Dr. Iva Greenwald; jjIs2277[RAD–SMAD+mec-7p::rfp],
lon-2(e678);jjIs2277, and sma-6(wk7);jjIs2277 (Tian et al., 2010)
obtained from Dr. Jun Liu.
Mapping and cloning of sma-21
We used SNP mapping (Davis et al., 2005) and aCGH (Maydan
et al., 2009) as previously described. Brieﬂy, a microarray was
designed for a 0.6 MB region delimited by the standard SNP mapping
protocol using an application at http://hokkaido.bcgsc.ca/SNPdetection/.
Processing of the microarray was done by Roche/NimbleGen. To conﬁrm
the polymorphisms identiﬁed by aCGH, we generated PCR fragments
ﬂanking the mutation sites and directly sequenced them. Primer
sequences are available on request. The PCR ampliﬁcation produces
752 bp fragment for the wild-type allele and a 277 bp fragment for
the deletion allele. For rescue, 10 ng/μl fosmid DNA was injected into the
gonadal syncytia of sma-21(wk156) hermaphrodites with myo-3::
mcherry (kindly provided by Dr. Hannes Bülow) as a marker (Mello
et al., 1991). Total concentration of the DNA at injection was adjusted to
100 ng/μg using Bluescript SK. yk cDNAs spanning this region were
obtained from Dr. Y. Kohara. The yk1586e04 was sequenced and the
predicted transcript structure was veriﬁed. Primers used for sequencing
the yk clone are available upon request.
Measurement of nuclear and cell numbers
We counted the number of nuclei in the hypodermis, seam cells
and intestine in wild-type and adt-2 mutant animals. DAPI staining
was used to label the intestinal nuclei. N2, adt-2 worms were ﬁxed
with acetone, washed with PMB (50 mM Na2HPO4 pH 7.5, 1 mM
MgCl2) and immersed in 500 μl/ml DAPI solution for 30 min. Worms
were then washed twice with PMB and the intestinal nuclei were
counted. The number of seam cell nuclei was counted using the
transgene wIs51 [SCM::GFP, unc-119(+)], a seam cell marker in adult
animals (Clucas et al., 2002). The number of nuclei in the hypodermis of
L4 animals was counted using the transgene arIs99 [dpy-7p::2Xnls::yfp],
a hypodermal reporter, which is expressed in hyp7 and other
hypodermal cells (Myers and Greenwald, 2005). Individual seam cell
perimeters were measured in L3 larvae using the ajm-1::gfp marker
(Mohler et al., 1998) which localizes to adherens junctions. The length of
the pharynx and the body size of the same L3 worms were also
measured. These markers were introduced into adt-2(wk156) by
standard genetic crosses. Images were taken using a confocal or
epiﬂuorescence microscope.
RNAi feeding
RNAi feeding was performed as described in Kamath et al. (2001).
Six L4 animals were transferred to feeding plates, incubated
overnight, transferred to fresh plates and the progeny were scored.
adt-2 expression
We used PCR fusion based approach to create adt-2p::gfp construct
(Hobert, 2002). We ampliﬁed 4492 bp region of genomic DNA
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upstream of adt-2 to the nearest adjacent gene and fused with a GFP
reporter. Primers used for fusion were:
adt-2A: 5′ GC GGA TCC TAA AAC TAT AGG AAA TTC GGA 3′
adt-2A*: 5′ GC GGA TCC TTT ATG TAA TAC TAA TAC TGG 3′
adt-2B: 5′ GAA AAG TTC TTC TCC TTT ACT CAT aat gtt gtt ctg gag ttg
gca gaa 3′
adt-2B*: 5′ GAA AAG TTC TTC TCC TTT AC TCA Ttg aga ata tgc aga ttt
cac aac g 3′
20 ng/μl adt-2p::gfp construct was microinjected to N2 hermaphrodites along with myo-3::mcherry as a transformation marker. Total
concentration of the DNA at injection was adjusted to 100 ng/μl using
Bluescript SK.
Analysis of body size measurements
To characterize the body size phenotype of adt-2, we created
growth curves by measuring the body lengths of wild-type N2 worms
and adt-2(wk156) at various times after embryo collection. Worms
were grown at 20°C and photographed using Axio Vision 3.00
software. The length of each worm was determined by drawing a
segmented line along the midline using the same software. To analyze
body width, adt-2(wk156) and adt-2(RNAi) adult worms were
photographed at 96 h after embryo collection and the width
measured at a position through the vulva in the center of the body.
For body length measurements of the single and double mutants,
96 h old worms (144 h for daf-4 and daf-4;adt-2 double mutant grown
at 15°C) were photographed using QC Capture 2.73.0 and the length
was measured using Image-Pro Express 5.1.0.12 software.
Lifespan assay
Synchronous animals were obtained by bleaching of gravid
hermaphrodites. 120 L4 worms from wild type, adt-2(wk156) and
adt-2(RNAi) were picked. Adult N2 worms also treated with adt-2
RNAi were tested for their lifespan. From each strain, the L4 worms
were divided into 12 plates with 10 worms per plate. Worms were
transferred to fresh plates every other day and the number of
surviving worms was counted. Worms were marked as dead if they
failed to respond to the nose tap with a platinum wire. Kaplan–Meier
survival analysis was used to compare the median lifespan of different
strains of animals.
Generation of double mutants
Double mutants containing mutations in the sma-6, daf-4, sma-2,
sma-3, sma-4, sma-9, sma-1 and rnt-1 genes were created by crossing
adt-2(wk156);him-5(e1490) males into the hermaphrodites of each
mutant and scoring progeny for the expected phenotypes. The rnt-1
(ok351) deletion mutation was conﬁrmed by PCR. All the other
mutations were conﬁrmed by complementation tests. che-2(e1033);
adt-2(RNAi), egl-4(n477);adt-2(RNAi), tax-6(ok2065);adt-2(RNAi),
cnb-1(ok276);adt-2(RNAi), pha-2(ad472);adt-2(RNAi), and pha-3
(ad607);adt-2(RNAi) double knockdowns were made by feeding
che-2, egl-4, tax-6, cnb-1, pha-2, and pha-3 mutant worms with adt-2
dsRNA expressing bacteria.
COL-19::GFP localization in adt-2(wk156)
In order to see the cuticle of adt-2(wk156), an adult speciﬁc marker
COL-19::GFP was used (Thein et al., 2003). kaIs[col-19::gfp];adt-2(wk156)
was constructed by crossing COL-19::GFP males into adt-2(wk156) hermaphrodites. The small hermaphrodites with COL-19::GFP reporter were
picked in the F2 generation. Plates bearing smalls and COL-19::GFP
reporter were selected and the cuticle was observed under the confocal

microscope. kaIs[col-19::gfp];adt-2(tm975/wk156) was made by crossing
kaIs[col-19::gfp];adt-2(wk156) males into adt-2(tm975)/+ hermaphrodites. We also treated COL-19::GFP expressing worms on adt-2(RNAi).
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